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Post-operative chemotherapy is often given to gastric carcinoma patients after 
surgical resection to reduce the likelihood of local recurrence or distant 
metastasis. The choice of anti-cancer drugs is usually based on the reported 
experience of large clinical trials rather than specific for the individual patient. 
The efficacy rate is low，partly due to drug resistance which may be acquired or 
intrinsic. p53 gene abnormality and overexpression of multi-drug resistance 
(MDR1) gene are believed to be major mechanisms in chemoresistance. 
The aims of this study 
1. To establish an in vitro assay to compare the relative sensitivity of the 
patient's tumor to a panel of chemotherapeutic agents. This assay will 
� help the clinicians in their choices of antitumor drugs with the ultimate 
goal of providing patient-specific individualized chemotherapy. 
2. To examine the relationship, if any, between 1) chemosensitivity and p53 
gene, and 2) chemosensitivity and expression of MDR1 gene. 
ii 
Materials and Methods 
A total of 31 gastric adenocarcinoma samples were subjected to 
chemosensitivity testing against five antitumor agents, 5-fluorouracil, adriamycin, 
cisplatin, daunorubicin, and epirubicin, at six concentrations. The 
chemosensitivity was expressed in term of ICso�the concentration of drug that 
inhibits 50% of the cell growth with respect to the control. p53 abnormalities 
were detected by immunohistochemistry with monoclonal antibody DO-7 and 
mutational analysis using single-strand conformational polymorphism (SSCP) 
and conformation sensitive gel electrophoresis (CSGE) for mutational hotspots 
in exons 4-9. MDR1 gene overexpression was studied by reverse-transciption 
polymerase chain reaction (RT-PCR). 
Results 
The tumors responded to the drugs in a dose dependent manner. The 
response to antitumor drugs is a unique characteristic of each tumor. No two 
tumors have identical ICso. The value of IC50 varied wide among the tumors. 
The distribution of IC50 for all five drugs approximated to normal curve. No 
correlation between chemosensitivity and clinical parameters was identified. 
Based on the limited data on the clinical outcome of 4 patients, the ICsoOf the 
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tumor for 5-fluorouracil correlated with the clinical response. Overexpression 
of p53 was detected in 65% of the samples. Only for cisplatin, but not the other 
four drugs, chemoresistance correlated with overexpression of p53. By SSCP/ 
CSGE, 52% of tumors were found to harbor p53 gene mutation in exons 4-9. 
No correlation between chemosensitivity and p53 mutation was found. MDR1 
gene was overexpressed in 56% of tumors. No correlation between MDR1 
expression and chemosensitivity was found. 
Conclusion 
This study has established an assay for determining gastric cancer 
chemosensitivity. This chemosensitivity test can be performed on surgical 
resection of gastric cancers and be completed within 6 weeks, paving the way to 
individualize postoperative chemotherapy in the future. Chemosensitivity did not 
correlate with p53 abnormality or MDR1 overexpression, suggesting that there are 
other factors that determine the final sensitivity to antitumor drugs. As neither 
these molecular markers nor the clinical parameters correlated with 
chemosensitivity, in vitro chemosensitivity testing cannot be replaced by molecular 
studies. Future studies should focus on the correlation of IC50 with clinical 
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1. INTRODUCTION 
1.1 Gastric carcinomas 
1.1a Epidemiology 
The incidence of gastric carcinoma has declined over the past 25 years. 
However, it remains the second most common cancer in the world (Globocan 
2000; Lambert et al. 2002; Tominaga 1987). It was estimated that there were 
798,000 new cases and 628,000 deaths around the world in year 1999 (Parkin 
et al. 1999). The distribution of this cancer amongst different populations is 
not uniform. In general, gastric carcinoma is a more serious problem in 
developing nations compared with the industrialized nations (Boland et 
al.1991). Gastric carcinoma occurs in extremely high incidences in certain 
geographic locations such as San Marino and Costa Rica (Correa 1992; 
Jackson et al. 1980). High incidence is also observed in Korea, Japan, and 
China (Globocan 2000). The incidence in Japan is 75 to 100 new cases per 
100,000 population per year (Munoz et al. 1997). In Europe, the incidence is 
between 20 to 40 per 100,000 population (lARC 1996). In contrast, the 
incidence of�gastric ancer in the United States is 6.9 cases per 100,000 
population (Lambert et al. 2002). Gastric carcinoma occurs more often in 
men with the male/female risk ratio of 1.5:1 (Nishikubo and Haskell 2001). 
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According to the Hong Kong Department of Health, the incidence of gastric 
cancer in Hong Kong was increasing from 1995 to 1997 (Chan 1999). In the 
year of 1999’ a total of 699 persons died of gastric cancer (Chan 1999). This 
is about 10 deaths per 100,000 population. Patients above the age of 60 are 
affected the most. 
1.1b Classification 
Approximately 95% of gastric cancers are adenocarcinomas, with the 
remainder consisting of lymphomas, carcinoids, and other sarcomas 
(Macdonald et al. 1982). The histological classification of gastric carcinoma 
is imperfect and imprecise. Several classifications have been defined with 
some being macroscopic and others being microscopic. The most widely 
used international classification of gastric carcinoma is that of Lauren, which 
was established in 1965. This system, which is the one recommended by the 
American Joint Committee on Cancer, recognizes both gross and microscopic 
features and divides the tumors into 'intestinal' and 'diffuse' (Lauren 1965). 
Intestinal tumor is characterized by epithelial cells that form discrete glands, 
either densely packed or surrounded by connective tissue, while the diffuse 
type carcinoma is characterized by sheets of epithelial cells or cells scattered 
2 
in a stromal matrix without evidence of gland formation. Diffuse type 
carcinoma tends to be cytologically less differentiated and may contain 
signet-ring cells, or secrete large amounts of extracellular mucin. The 
intestinal type is more common, making up more than 50% of Lauren's original 
cohort of patients. The diffuse type accounted for 25%-35%, and about 
12-16% could not be classified (Borch et al. 2000; Janssen et al. 1991; 
Lundegardh et al. 1991). The intestinal type is more frequent among 
high-risk populations, such as Japan, with a preference for men and older 
individuals. It is also associated with atrophic gastritis and intestinal 
metaplasia (Hotz and Goebell 1989). In contrast, the diffuse type is typical of 
populations at low-risk of gastric cancer, with a slight preference for women 
and younger patients (Ho 1996). As the total incidence of gastric cancer 
declines worldwide, the intestinal type appears to be responsible for the 
declining number (Correa and Chen 1994; Munoz and Asvall 1971). However, 
the diffuse subtype is proportionally becoming more common (Neugut et al. 
1996). In contrast, an increase in tumors of the cardia has been described 
(Blot et al. 1991; Powell and McConkey 1991). 
1.1c TNM Staging 
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Until 1984 there were three conflicting schemes for staging gastric carcinoma -
the Japanese system, the European system of the Union Internationale Contra 
le Cancre, and the TNM system of the United States (Roberts and Niederhuber 
1993). After much discussion, the TNM system has been accepted as 
universal for classifying the extent of cancer spread. The International TNM 
system was outlined in the Manual for staging of cancer of the American Joint 
Committee on Cancer in 1992, and was updated in 1997 (Fleming et al. 1997). 
The detailed TNM classification of gastric tumors is listed in appendix 1. The 
letter T describes the extent of the primary tumor (T); the letter N represents 
the absence or presence of metastasis to nearby lymph nodes, and the letter 
M describes the absence or presence of distant metastasis. The size and 
location of the tumor are considered to be less important (Haskell and 
Nishikubo 2001). TNM staging is a term used to define the size and physical 
extent of a cancer, and it should be used only for combination of T, N and M 
categories (UlCC 2001). The TNM stage grouping for gastric tumor is listed 
in appendix 2. 
1.1cl Prognosis 
丁he relative five-year survival rates differ between countries. TNM stage of 
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the tumors at presentation is the major determinant of five-year survival rates. 
In the European countries, the overall five-year survival rates ranged from 9% 
to 27% (Faivre et al. 1998). In the United States, the overall five-year survival 
rate was 26% (Karpeh and Brennan 1998). Using the TNM classification as 
recommended by the American Joint Committee on Cancer, the five-year 
survival rate in the United States was 71%, 37%, 11%，and 5% for stage I, II, III, 
and IV respectively (Hundahl et al. 1997). Similar finding was also observed 
in European countries such as Netherlands (Pinheiro et al. 1999). Factors, 
including age of the patient, tumor location, depth of invasion, and histological 
type, also have impact on the overall prognosis. Level of invasion is inversely 
correlated with survival (Kimberly et al. 1997). The importance of depth of 
tumor penetration into the gastric wall is underscored by the group of patients 
with early gastric cancer. The term 'early' refers specifically to those lesions 
that are confined to the mucosa or submucosa, independent of lymph node 
metastases (Murakami 1979). Five-year survival rate over 90% has been 
reported for early gastric cancer from western investigators (Oliveira et al. 
1988). In Japan, early gastric cancer has a five-year survival rate ranged 
from 70 to 90 percents (Roberts and Niederhuber 1993). The five-year 
survival rate falls to 50% when the gastric muscularis is involved and down to 
5 
40% when the serosa is involved. In addition, advanced age portends an 
unfavorable prognosis among patients with gastric cancer (Kimberly et 
al.1997). Moreover, gastric cancers located in the proximal stomach tend to 
be associated with a poor outcome (Kajiyama et al. 1997; Setala et al. 1996). 
A study found five-year relative survival rate was 10.4% for patients with 
cancer of the gastric cardia as compared to 19.4% for patients diagnosed with 
non-cardiac stomach cancer (Hansson et al. 1999). It is noteworthy that 
studies from the United States (Blot etal. 1991)，Sweden (Hansson et al. 1993)， 
Iceland (Jonasson et al. 1994)，England (Rios- Castellanos et al.1992), and 
the Netherlands (Crannen et al. 1991) point to an increase in incidence of 
cancer of the gastric cardia. Furthermore, lesions of the gastric cardia now 
constitute approximately 40%-50% of gastric carcinomas in some regions 
(Harrison and Fielding 1995). Patients with diffuse-type tumors have a worse 
prognosis than those with an intestinal type (Bevan and Houlston 1999). 
1.1e Etiology 
Worldwide studies on the epidemiology of gastric carcinoma have indicated 
that intestinal and diffuse types of gastric carcinoma may have different 
etiologies (Hotz and Goebell 1989). Environmental factors and predisposing 
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conditions have been suggested to play a more permissive role in the 
pathogenetic chain of developing intestinal type carcinoma than that of diffuse 
type carcinoma (Crawford 1997; Wang 1995). In contrast, diffuse type 
carcinoma is affected to a larger extent by genetic factors as compared to 
environmental factors (Howson et al. 1986). 
Early studies on possible causative agents have emphasized the role of 
dietary factors. High consumption in salted or smoked fish, pickled 
vegetables or well-cooked meats has been commonly cited as contributory to 
gastric cancer (Dungal and Sigurjonsson 1967; Ward et al.1997). Foods high 
in carbohydrate content, such as pastas, pastries and bread are associated 
with an increased risk of developing gastric cancer (Harrison et al. 1997). On 
the other hand, fruit and fiber have been found to be protective (Harrison et al. 
1997). Other factors include tobacco use, which is associated with a twofold 
increase in the risk of developing gastric cancer (Gammon et al. 1997). In 
addition, certain occupations, such as nickel plating and coal mining, may 
increase the risk of developing gastric carcinoma (Gammon et al. 1996). 
Besides, there are also a number of predisposing conditions that provide clues 
as to the pathogenesis of gastric cancer. These conditions include pernicious 
anemia, the post-gastrectomy state (after partial resection for benign disease), 
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and chronic atrophic gastritis with intestinal metaplasia (Davis 1993). 
Intestinal type carcinoma of the stomach is often associated with widespread 
chronic atrophic gastritis and intestinal metaplasia (Wang 1995). It was 
hypothesized that intestinal type carcinoma emerged with a progression from 
superficial gastritis to chronic atrophic gastritis, intestinal metaplasia, dysplasia, 
carcinoma in situ, and ultimately invasive carcinoma (Correa et al. 1975; 
Correa 1988). 
Infection of H pylori is the most common known cause of chronic gastritis and 
has been suspected to play a role in gastric carcinogenesis. With the 
exception of few studies, most studies have indicated H pylori infection is a risk 
factor for gastric carcinoma. In the United States, a case-control study 
drawing from a data base of nearly 129,000 persons, of whom 186 had gastric 
adenocarcinoma, reported that 84% of the patients with cancer had serologic 
evidence of a prior infection with H pylori, as compared with 61% of controls 
matched for age, sex, and race (Parsonnet et al. 1991a). The authors 
calculated an odds ratio of 3.6，and concluded infection with H. pylori is 
associated with an increased risk of gastric adenocarcinoma. However, a 
similar control case study in Korea, involved 160 gastric cancer patients and 
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160 age-matched controls, found no evidence of H. pylori infection 
predisposing to gastric cancer (Kim et al. 1997). 
Comparisons have been made to determine the frequency of H pylori infection 
between histological types, and the data indicated that H pylori is more often 
associated with intestinal type carcinoma than diffuse type (Buruk et al. 1993; 
Endo et al. 1995; Parsonnet et al. 1991b). Nevertheless, H pylori infection is 
also believed to be a risk factor for diffuse type gastric carcinoma (Roberts and 
Niederhuber 1993). 
Although the exact risk factors for the diffuse type carcinoma are still not 
defined (Crawford 1997), hereditary factors have been suggested (Bevan and 
Houlston 1999; Goldberg 2000). Study has reported a proportion of diffuse 
gastric cancer families have germ-line E-cadherin mutations (Gayther et al. 
1998). Lynch et al. also suggested E-cadherin mutation strongly predicts 
susceptibility to diffuse gastric carcinoma (Lynch et al. 2000). Another risk 
factor associated with diffuse type gastric carcinoma includes blood group A 
(Wu et al.1997). 
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1.1f Genetics alteration in gastric cancer 
It is believed that the development of gastric cancer, in which normal epithelial 
cell is transformed into malignant cell, is a multistep process and results from 
an accumulation of multiple gene abnormalities. Tumor suppressor genes, 
protooncogenes, and genes coded for cell adhesion molecules have been 
reported to be associated with gastric cancer. 
Tumor suppressor genes included p53, adenomatous polyposis coli (APC), 
Deleted in Colon Cancer (DCC), phosphatase and tensin hornolog deleted on 
chromosome 10 {PTEN), and fragile histidine triad {FHIT) genes have been 
reported to be altered in gastric cancer. 
丁he APC gene encodes a large protein with multiple cellular functions and 
• interactions, including roles in signal transduction，mediation of intercellular 
adhesion, stabilization of the cytoskeleton and possibly regulation of the cell 
cycle and apoptosis (Fearnhead, 2001). Furthermore, APC gene product is 
known to bind to the beta-catenin. Both APC and beta-catenin are members 
of the Wnt/Wingness signal transduction. In the Wnt pathway, beta-catenin 
plays a role as a transcription activating protein by forming complex with the 
TcRef family of transcription factors, which transfers cell proliferation signals 
to the nucleus (Nakamura 1997). The binding of APC protein to beta-catenin 
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promotes the degradation by the proteosome system and downregulates 
beta-catenin (Orford et al. 1997). 
^PC gene mutation in gastric cancer has been reported and is limited to 
particular histotypes. High frequency of APC gene mutation is found in 
intestinal type gastric cancer (Nakatsuru et al. 1992). In one study, about 
33% of the intestinal type gastric cancer had APC gene mutation; however, no 
mutation in APC gene was found in the diffuse type (Ebert et al. 2002). Up to 
60% of the intestinal type tumors have loss of heterozygosity (LOH) of 
chromosome 5q, in which the APC gene locus has also been reported (Sano 
et al. 1991 )• Similarly, mutation in the beta-catenin gene is found exclusively 
in the intestinal type (Park et al. 1999，Ebert et al. 2002). Such mutation is 
associated with the increased beta-catenin mRNA levels (Ebert et al. 2002). 
These genetic alterations may stabilize beta-catenin and contribute to loss 
growth control in tumorigenesis of tumors. 
D e c is a candidate tumor suppressor gene. However, the function of DCC 
remains elusive. Previously, the expression of DCC gene has been shown to 
induce apoptosis or cell cycle arrest (Chen et al. 1999). Inactivation due to 
LOH at the chromosome18q21 region, involving the DCC locus, has been 
reported in about 20-30% of the gastric cancer (Candusso et al. 2002; Cho et 
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al. 1996). However, as high as 60% of gastric cancer has been reported to 
harbor LOH at the DCC locus (Uchino et al. 1992). In addition, both 
decreased expression of DCC mRNA (Kataoka, 2000) and DCC protein (Sato 
et al. 2001) have been observed in 40% and 78% of gastric cancers 
respectively. However, inactivation of this gene due to mutation has not been 
found (Sato et al. 2001). 
Recently, abnormalities, includes promoter methylation and reduced 
expression of the PTEN gene are association with gastric tumor progression 
(Kang et al. 2002). PTEN gene is a tumor suppressor gene located on 
chromosome 10q23.3 (Myers et al. 1997). Biochemical analysis of PTEN has 
revealed that it is a member of the family of dual-specificity protein 
phosphatases (DSPs) that dephosphorylate serine, threonine, and tyrosine 
residues (Myers et al. 1997). It is involved in the Akt signaling pathway. The 
phosphatase activity of PTEN down-regulates the signaling of Akt, which 
suppresses apoptosis and promotes cell survival (Sun et al. 1999). PTEN is 
also known to induce G1 cell cycle arrest (Li and Sun, 1998). It inhibits the 
spreading and migration of cells (Gu et al. 1998)，and regulates tumor-induced 
angiogenesis (Wen et al. 2001) and participates in apoptosis (Choi et al. 2002). 
Aberrant methylation of PTEN gene promoter has been detected in 39% of 
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gastric cancer, and the promoter methylation is correlated to the loss of PTEN 
protein expression (Kang et al. 2002). 
FHIT gene is located at the FRA3B site of chromosome 3p14.2 and is so far 
the only example of a relatively well studied gene located in a constitutive 
fragile region (Ohta et al. 1996). FHIT reduces the intracellular level of 
diadenosine triphosphate, which plays a role in the control of cell growth 
(Barnes et al. 1996; Murphy et al. 2000). LOH within the FHIT gene has been 
detected in 84% of the gastric tumor (Huiping et al. 2002). Reduced FHIT 
expression has been reported (Baffa et al. 1998), and its expression is 
associated with disease stage and survival (Capuzzi et al. 2000). However, 
mutation of this gene in gastric carcinoma has not been reported (Tamura et al. 
1997; Huiping et al. 2002). 
Growth factor, growth factor receptor, signal transducer and nuclear protein 
are examples of protooncogenes. Amplification, rearrangement, point 
mutation and translocation are some mechanisms that cause activation of 
protooncogenes. Receptor tyrosine kinases, especially c-met, K-sam and 
c-erbB2, have been reported to be altered in gastric cancer. 
Among these, alteration of c-met is the most implicated in gastric carcinoma. 
This gene codes for the hepatocyte growth factor (HGF) receptor, a 
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transmembrane protein. Amplification of this gene is frequently found in 
advanced gastric cancer, and more than 50% of gastric cell lines harbor the 
amplification of this gene (Kuniyasu et al. 1992). The majority of gastric 
cancers overexpress two different c-met transcripts 7.0kb and 6.0kb in size. 
The 6.0 kb transcript is expressed preferentially in cancer tissue of the 
stomach and its expression correlates with tumor staging, lymph node 
metastasis and depth of tumor invasion (Kuniyasu et al. 1993). In addition, 
both the mRNA expression and protein expression of c-met gene are highly 
upregulated in the gastric tumor as compared to the normal gastric tissue 
(Huang etal. 2001). 
K-sam (KATO-III cell-derived stomach cancer amplified gene), which was 
..isolated from KATO-III signet ring cell carcinoma, encodes a receptor tyrosine 
kinase，that belongs to the heparin-binding growth factor receptor, or fibroblast 
growth factor receptor, gene family. (Hattori et al. 1990; Katoh et al. 1992). At 
least four types of transcription variants of K-sam, encoded both membrane 
bound receptor and secreted type receptor, are known (Kato et al. 1992). 
Amplification of this gene (Tahara et al. 1993), and overexpression of K-sam 
protein take place preferentially in diffuse type than in intestinal type (Hattori et 
al. 1996). 
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c-erbB2 is one of the members of epidermal growth factor receptor gene family. 
It encodes a 185kDa glycoprotein with tyrosine kinase activity (Akiyama et al. 
1986). In contrast to K-sam, amplification of c-erbB2, at the locus 
17q12-q21.32, is preferentially in intestinal type than in diffuse type (Vidgren et 
al. 1999). In addition, overexpression of this protein is also found 
predominantly in the intestinal type than in diffuse type (Sanz-Ortega 2000). 
It is believed that the overexpression in tumors is due to gene amplification 
(Becker et al. 2000). 
Lastly, genetics alterations in the apoptosis associated genes have been 
reported to be associated with gastric cancer. For examples, the death 
receptor-ligand systems such as Fas-Fas receptor, TNF-TNF receptor and 
•TRAIL-TRAIL receptor are important pathways for apoptosis. The death 
receptor interacts with a protein called Fas-associated death domain (FADD). 
As a result, inactive procaspases such as procaspase 8 and procaspaselO are 
recruited, leading to apoptosis (Fernandes-Alnemri et al. 1996; Ng et al. 1999; 
Vincenz and Dixit, 1997; Wang et al. 1999). LOH and mutations in the death 
receptors such as the Fas or KILLER/DR5 have described in gastric cancer 
(Park et al. 2001a，2001b). Moreover, LOH at chromosome 2q33，where the 
caspase-8 and caspase-10 genes resides, is frequent in gastric cancer 
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(Nishizuka et al. 1998). Missense and nonsense mutations of the caspase 10 
have also been found, leading to the loss of apoptotic signaling function (Park 
et al. 2002). 
人 2 Treatment 
1 -23 Surgery, chemotherapy and others 
Surgery，chemotherapy, radiotherapy or endoscopic lasers are the choices of 
treatment for gastric carcinoma. Surgery remains the only potentially curative 
therapy for gastric cancer (Portlock 1991). The size and location of the tumor 
dictate the type of operation to be performed (Ramming 2001). However, in 
the case of advanced gastric cancer in which surgical treatment is not possible, 
chemotherapy has offered an alternative that mainly aims to palliate patients' 
symptom. The role of chemotherapy in the treatment of gastric cancer cannot 
be dismissed, considering the fact that about 50% gastric cancer patients in 
the Western world present with non-resectable disease (Green et al. 2002). 
In addition, recurrence loco-regionally in the gastric bed, perigastric lymph 
nodes，peritoneal surfaces, pelvis, and liver often occur after curative resection 
(Woodward and Levin 1999). Studies showed that the rate of local 
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recurrence approaches 40% even after apparent complete resection 
(Gunderson and Sosin 1982; Landry et al. 1990; Saito et al. 2001). 
Chemotherapy is often employed as part of multi-modality adjunct to surgical 
treatment. 
Chemotherapy may be defined as the application of drugs to kill or inhibit the 
growth of viruses or foreign cells, such as bacteria, in the body. Cancer cells 
can be considered as "foreign" in this sense. Chemotherapy before surgery 
is termed neoadjuvant therapy. It aims at improving resectability by 
decreasing the size and extent of the tumor (downstaging) and eliminating 
systemic micrometastases (Crookes et al. 1997; Woodward and Levin 1995). 
It can also palliate symptoms (Woodward and Levin 1999). However, it may 
increase the tumor burden associated with delayed treatment and allow the 
emergence of a resistant clone (Woodward and Levin 1995). In contrast, 
chemotherapy after surgery is termed adjuvant therapy. The rationale is to 
eradicate any residual disease following removal of the main tumor, and thus 
reduce the possibility of local recurrence (Woodward and Levin 1995). In fact, 
chemotherapy has a favorable impact on the survival time (Green et al. 2002). 
Radiotherapy and endoscopic lasers have only minimal role in the treatment of 
gastric cancer (Roberts and Niederhuber 1993). Radiation as a primary and 
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exclusive therapy in the treatment of gastric cancer is an inadequate modality 
primarily because the initial bulk of disease is often large (Woodward and 
Levin 1995). In addition, gastric carcinoma is relatively radio-resistant, and 
requires high doses of radiation resulting in major side effects in the 
surrounding tissues (Goldberg 2000; Woodward and Levin 1995). Besides, 
side effects such as anorexia, nausea, and vomiting are often severe 
(Woodward and Levin 1995). 
1.2b Response rate of treatments in previous studies 
Currently, 5-FU, cisplatin, and adriamycin are common anticancer drugs used 
in the treatment of gastric cancer. The drugs can be applied as a single agent 
or combination agents; or in adjuvant or neoadjuvant treatment setting. In 
addition，the combination of chemotherapy, radiotherapy and surgical 
resection has been practiced. 
Previous clinical trials have suggested most chemotherapeutic agents when 
used as a single agent offer about 20% to 30% response rate. For example, 
in 5-FU treatment, the overall response rate is 23% (Cocconi et al. 1982; 
Comis and Carter 1974; Kolaric et al. 1986). However, a 31% response rate 
was reported by changing the conventional bolus administration to a low-dose 
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continuous infusion (Moynihan et al. 1988). As a single agent, adriamycin 
offered a 25% response rate (Levi et al. 1986)，and cisplatin gave a 19% 
response rate (Beer et al. 1983; Lacave et al. 1983). Yet, a 36% response 
rate was reported in epirubicin treatment (De Vries et al. 1989). 
Most recent chemotherapeutic treatments contain combination of drugs in the 
hope of enhancing antineoplastic activity. Current multidrug regime in gastric 
cancer treatment usually contains 5-FU, cisplatin, or adriamycin. FAM (5-FU, 
adriamycin and mitomycin) and FAMe (5-FU, adriamycin and methyl-CCNU) 
are examples of multidrug chemotherapy regime. They were also the almost 
first generation of combination regime. As compared to 5-FU, which offered a 
18% response rate as a single agent, FAM offered a 38% response rate 
(Cullinan et al. 1985). The FAMe regime also gave a 47% response rate as 
compared to adriamycin, which gave a 24% response rate (The 
Gastrointestinal Tumor Study Group 1979). However, study by the North 
Central Cancer Treatment Group found no survival advantage of the FAMe 
regime over 5-FU alone for treatment of advanced gastric cancer (Cullinan et 
al. 1994). 
Example of another type of combination therapy is the combination of 
etoposide, adriamycin, and cisplatinum (EAP). It was developed initially on 
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the basis of the synergism seen between etoposide and cisplatin in murine 
models (Wang, 1995)，and the lack of cross-resistance between etoposide, 
doxorubicin, and cisplatin (Schabel et al. 1983). Preusser and colleagues 
demonstrated a 64% response rate (Preusser et al. 1989). However, 
subsequent studies revealed a 18% and 44% response rates. (Taguchi et al. 
1989; Rath et al. 1990). In addition, the regimen is associated with rather 
significant toxicity, such as myelosuppression (Preusser et al. 1989; Lerner et 
al. 1992). 
Radiation as a primary and exclusive therapy in the treatment of gastric cancer 
is an inadequate modality primarily because the initial bulk of disease 
decreases efficacy. There is also limited tolerance of the surrounding tissues. 
However, radiation can offer palliation, particularly in conjunction with 
chemotherapy. Of patients with gastric cancer, 50% to 75% derive some 
relief with radiation from symptoms such as obstruction, pain, or bleeding 
(Smalley et al. 1992). Multi-drug regimens in conjunction with radiation have 
been examined. In a randomized trial, the combination of 5-FU and radiation 
offered a 12% survival at five years as compared to 0% by radiation alone 
(Moertel et al. 1969). Current chemoradiotherapy usually applied in adjuvant 
or neoadjuvant setting. Lowy and colleagues reported 63% of patients who 
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had undergone chemoradiation prior to surgical resection had pathologic 
evidence of significant treatment effect (Lowy et al. 2001 )• In a recent report, 
556 patients were involved in a randomized trial (Macdonald et al. 2001). 
Combination chemotherapy (5-FU and leucovorin) and radiation were given to 
281 patients after surgery; the remaining patients were given surgical 
treatment. The result indicated overall survival was significant better in the 
postoperative chemoradiotherapy arm than the surgery-only arm. The 
median duration of survival was 36 months in the postoperative 
chemoradiotherapy group versus 27 months in the surgery-only group. 
1.2c Chemotherapeutic Drugs 
At present, a number of chemotherapeutic drugs are available in the treatment 
of gastric carcinoma. They are classified into different classes. Examples 
are the antimetabolites (5-fluorouracil), mitotic plant derivatives, antitumor 
antibiotics (daunorubicin, epirubicin, and adriamycin), alkylating agents 
(cisplatin), hormonal agonist and antagonists, and topoisomerase inhibitors. 
Combination chemotherapy is used more often than single-agent 
chemotherapy because it is hypothesized that combination chemotherapy 
increases efficacy by synergism effect of the drugs. 
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5-fluorouracil (5-Fu) and cisplatin (CDDP) are the two drugs most often used in 
the treatment of gastric carcinoma (Findlay and Cunningham 1993; Janunger 
et al. 2001). They are known to be relatively active against gastric carcinoma 
(Crookes.et al. 1997; Leichman and Berry 1991). 
1.2c (1) 5-fluorouracil (5-FU) 
5-FU is a cell cycle-phase-dependent antimetabolite, which was developed by 
Heidelberger and Ansfield in 1957. It was also the first antitumor drug applied 
in gastric carcinoma (Childs et al. 1968; Moertel et al. 1969). 5-FU is a 
pro-drug that enters cells by an active, membrane-carrier transport process. 
After the entrance into cells, 5-FU is converted into its active metabolites. 
One metabolite, 5-fluorodeoxyuridylate (FdUMP), forms a complex with 
enzyme thymidylate synthetase (TS) and interferes with DNA synthesis. 
Inhibition of TS has been reported to lead to DNA strand breakage. K may 
also be incorporated into DNA, with subsequent effects on DNA repair and the 
induction of strand breaks (Curtin et al. 1991). Another metabolite, 
fluorouridine triphosphate (FUTP) inhibits RNA metabolism by incorporating 
into nuclear RNA (Pritchard et al. 1997). Other biochemical effects of 5-FU 
include inhibition of RNA synthesis (Ardalan and Glazer 1981) and interference 
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of the excision repair enzyme function (Wurzer et al. 1994). 
1.2c (2) c/s-diamminedichloroplatinum (Cisplatin) 
Cisplatin was introduced in the 1960’s (Zwelling and Kohn 1979). Cisplatin is 
a planar platinum complex consisting of two chloride-leaving groups in the cis 
position around platinum. Cisplatin functions as a non-cell cycle specific, 
alkylating agent. In the blood, cisplatin is present in an inactive, uncharged 
state due to the high concentration of chloride ions. After cisplatin enters 
cells by passive diffusion (Binks and Dobrota 1990)，its two chloride ligands 
are replaced by water molecules; consequently, it becomes a positively 
charged platinum complex that is active (Kartalou and Essigmann 2001). The 
active complex then reacts with nucleophilic sites on intracellular 
macromolecules to form DNA, RNA, and protein adducts (Kartalou and 
Essigmann 2001). Being an alkylating agent, it mainly binds covalently to the 
number 7 position (N7) nitrogen of guanine in DNA, leading to intra-strand 
cross-linking and other forms of binding such as inter-strand cross-linking. 
丁he major consequence is inhibition of DNA as a template for cell replication. 
Cisplatin was found to cause telomere loss as an additional form of cytotoxicity 
(Ishibashi and Lippard 1998). Other mechanisms of cisplatin cytotoxicity 
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include mitochondrial damage, decreased ATPase activity, and altered cellular 
transport mechanisms (Golden Standard Multimedia 2001; Melendez-Zajgia et 
al. 1999). 
1.2c (3) Doxorubicin (Adriamycin) 
Adriamycin is an anthracycline antibiotic developed in the 1970’s in Italy 
(Gewirtz 1999). It is a natural product isolated from Streptomyces peucetius 
var caesius. The drug is considered cell cycle non-specific. The major 
mechanism of this antibiotic drug is intercalating with DNA. That is, the 
planar ring region of the drug stacks between two adjacent nucleotide bases of 
DNA. The drug is non-covalently, although firmly, bound to DNA and distorts 
the shape of the double helix, resulting in inhibition of RNA or DNA synthesis 
(Haskell and Rosen 1995; Pigram etal. 1972; Young etal. 1981 )• Adriamycin 
also binds to and stabilizes DNA- topoisomerase II complex. As a result, 
double-stranded DNA break is induced to relieve the topological strain caused 
by drug interaction (Cummings et al. 1991; Ross and Bradley 1981; Tewey et 
al. 1984). In addition, adriamycin generates free radicals by adriamycin-iron 
complex with consequent induction of DNA damage or lipid peroxidation (Banfi 
et al. 1992; Muindi et al. 1984). Adriamycin can also alkylate DNA, resulting 
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in DNA cross-linking and the inhibition of DNA synthesis (Taatjes et al. 1996). 
1.2c (4) Daunorubicin 
Daunorubicin is a natural product isolated originally from Streptomyces 
caeruleorubidus in 1962 and was known as rubidomycin. It was later isolated 
from Streptomyces peucetius and called daunorubicin. The drug is cell cycle 
nonspecific, but the majority of action occurs in the S phase (Golden Standard 
Multimedia 2001). As an analog of doxorubicin, daunorubicin differs from 
doxorubicin by lacking a single hydroxyl group at the acetyl side chain of the 
9-position of the D-ring in the aglycone portion of the molecule. The 
mechanisms of action of daunorubicin are essentially the same as those of 
doxorubicin (Haskell and Rosen 1995). 
1-2c (5) Epirubicin 
Epirubicin is a second-generation anthracycline (Furukawa et al. 1998), a 
derivative of doxorubicin. It is considered as cell cycle non-specific. Similar 
“ t o daunobricin, maximum killing occurs during the S phase of the cell cycle 
(Cersosimo and Hong 1986). Epirubicin is a stereoisomer of adriamycin 
differing in the orientation of the hydroxyl group on carbon atom four of the 
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hexopyranosyl sugar (Arcamone 1987). Ks mechanism of action is similar to 
that of doxorubicin (Cersosimo and Hong 1986). At equimolar doses, 
therapeutic index of epirubicin is more favorable than that of adriamycin 
(Cersosimo and Hong 1986). Importantly, fewer incidences of toxicity, 
includes myelotoxicity and cardiotoxicity are associated with epirubicin than 
those with adriamycin (Robert 1994; Wils 1986), 
1.2d Toxicity of chemotherapeutic drugs 
The toxicity and side effect associated with the administration of 
chemotherapeutic drugs are well documented. Here is a summary of the 
main forms of toxicity associated with the anti-tumor drugs used in gastric 
cancer. 
1.2d (1) Side effects of 5-FU 
丁he toxicity of 5-FU is strongly influenced by the dosage used and the route 
and duration of drug administration. Bone marrow suppression is the main 
form of toxicity when it is given by bolus injection (Haskell and Rosen 1995). 
On the other hand, oral mucositis, diarrhea and hematological dysfunction are 
the predominant forms of toxicity when it is given by continuous intravenous 
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infusions (Spicer et al. 1988). 
1.2d (2) Side effects of anthracyclines (adriamycin, daunobicin, epuirbicin) 
The toxicity of daunorubicin and epuirbicin is essentially the same as 
doxorubicin (Haskell and Rosen 1995). Cardiotoxicity is a serious side effect 
of treatment with anthracyclines (Hrdina et al. 2000). The cardiotoxicity is 
thought to be related to the anthrachinone ring system in the presence of 
magnesium and iron ions (Hershko et al. 1993; Hochsster et al. 1995; Minotti 
et al. 1999). When anthracycline enters cardiac cells, it is reduced to an 
anthracycline free radical that is rapidly oxidized with oxygen to form the 
original drug and superoxide anions. Normally, these radicals are converted 
back to oxygen via gluthathione peroxidase; however, the heart is essentially 
devoid of this enzyme. Consequently H2O2 is forced to react with ferrous ions 
to form the highly toxic superhydroxide free radical that causes severe lipid 
peroxidation leading to extensive mitochondrial destruction. However, the 
side effect is less severe in daunorubicin (Aubel-Sadron and Londos-Gagliardi 
1984). Compared with adriamycin, epirubicin can be administered in higher 
dose before cardiotoxicity occurs (Cersosimo and Hong 1986). • 
Myelosuppression and mucositis are also common toxic side effects in 
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adriamycin, epuirbicin and daunorubicin (Cersosima and Hong 1986; Feld et al. 
1992; Haskell and Rosen 1995). 
1.2d (3) Side effects of cisplatin 
Myelosuppression, gastrointestinal toxicity, peripheral neuropathy, ototoxicity 
and nephrotoxicity are the prominent toxicity associated with the administration 
of cisplatin (Fillastre and Raguenz-Viotte 1989’ Krakoff 1979). Other side 
effects such as cardiotoxicity and respiratory difficulties have also documented 
(Berman and Boly 1991). 
1-3 Mechanisms of drug resistance 
1.3a Drug resistance 
Apart from the usual side- effects of anti-cancer drugs, another problem during 
treatment is the development of drug resistance, either acquired or intrinsic. 
The term drug resistance is an ill-defined entity, which means different things 
to different people. For clinicians, resistance is the failure of the patient to 
respond to treatment (Sevin et al. 1993). The response to chemotherapy can 
be measured as a clinical reduction of measurable tumor size, a 
progression-free interval, a disease-free interval, survival time, a surgical 
28 
reassessment, or by sequential analyses of tumor markers. For tumor 
biologists, drug resistance is a cellular phenomenon and can be defined as 
"failure to achieve cytotoxicity at physiologically achievable concentration" 
(Sevin et al. 1993). Resistance to anti-cancer drugs is one of the major 
factors accounting for the poor clinical response to chemotherapy (Chung et al. 
1996). 
1.3b P-glycoprotein {MDR1 gene) 
Clinically, the term multi-drug resistance (MDR) originally came from studies 
using cell lines selected in vitro for resistance to a single agent. Subsequently, 
the cell lines exhibited broad cross-resistance to other chemically-unrelated 
agents to which the cells had never been exposed. This phenomenon is 
termed multidrug resistance (MDR) (Mooter and Stoter 1996). The classes of 
drug involved include anthracyclines, vinca alkaloids, colchincine, etoposide, 
actinomycin D, mitoxantrone, methotrexate and taxol (Davies and Hickson 
1996). All of these cross-resistance drugs are between 300-900 molecular 
weight in size; they are amphiphatic, and they enter the cell by passive 
diffusion. Further studies show the resistance is owing to the decreased drug 
accumulation as a result of an energy-dependent, unidirectional drug efflux 
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pump with a broad substrate specificity (Dano 1973). 
P-glycoprotein was the first human ABC (ATP binding cassette) superfamily of 
transport proteins shown to confer resistance to multiple chemotherapeutic 
drugs (Bradley et al. 1989). It was first discovered by Juliano and Ling in 
1976 as a large glycoprotein in the plasma membrane of drug-resistant 
Chinese hamster ovary cells that display altered drug permeability (Juliano 
and Ling 1976). The letter P denotes the permeability of the glycoprotein in 
the MDR cells. It took a long time, however, before scientists were convinced 
that P-glycoprotein is an energy-dependent drug efflux pump that binds and 
transports drugs against a drug concentration gradient and at the expense of 
adenosine triphosphate hydrolysis (Borst and Schinkel 1997; Germann 1996). 
丁his molecule expels cytostatic drugs from the cytoplasm, causing drug 
resistance at least in vitro (Hill 1993; Nielsen and Skovsgaard 1992). 
The gene encoded P-glycoprotein is now known as MDR1 gene (Ueda et al. 
1986). It was mapped to chromosome 7 at bands q21.1 (Calien et al. 1987). 
丁he complete intron/exon gene structure of the human MDR1 has been 
worked out (Chen et al. 1990). The MDR1 gene includes 28 exons with a 
total span of greater than 100kb (Chen et al. 1990). The gene is transcribed 
into a 4.5-kilobase mRNA (Roninson et al. 1986). MDR1 mRNA can be 
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transcribed from two different promoters, an upstream and a downstream 
promoter, with the downstream promoter preferentially expressed in most cell 
type (Ueda et al. 1987b, 1987c). The mature form of P-glycoprotein has a 
molecular weight of 170kD, and is about 1280 amino acids long (Chen et 
al.1986; Hamada and Tsuruo 1988). It is a membrane glycoprotein which 
consists of two halves that share a high degree of sequence homology (Chen 
et al. 1990). Each half of the protein includes a short highly hydrophilic 
N-terminal segment, a long hydrophobic region with six transmembrane 
segments, and a relatively hydrophilic region which contains consensus 
sequences for a nucleotide-binding site (Chen et al. 1990; Croop 1993; 
Gerlach et al. 1986; Germann 1993). The nucleotide-binding site is 
responsible for the ATP binding and hydrolysis; thus, it supplies energy for 
translocation of a wide range of substrates across biological membrane 
(Cornwell et al. 1987; Hamada and Tsuruo 1988). The antitumor drugs 
adriamycin and daunorubicin are known substrates for P-glycoprotein (Kerb et 
al. 2001). 
Different P-glycoprotein isoforms have been identified and are encoded by a 
family of closely related genes. They are referred to as pgp genes in 
hamsters and rats, mc/r genes in mice, and MDR genes in man (Deuchars et al. 
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1992; Ng et al. 1989). Based on their 3'-untranslated regions, the 
mammalian multi-drug resistance genes are divided into three classes of 
genes’ termed class I，class II and class III (Ng et al. 1989). Overexpression 
of class I or class II P-glycoproteins renders cells multi-drug resistant, while 
class III P-glycoproteins are not capable of conveying MDR (Mooter and Stoter 
1996). Only two P-glycoprotein isoforms, MDR1 and MDR2 (or MDR3)，are 
found in humans (Chin et al. 1989; Germann, 1996). They belong to class I 
and class III P-glycoprotein respectively. The role of MDR2 in human remains 
undetermined. The two isoforms share about 80% amino acid homology. 
MDR1 gene expression is frequently observed in different human tumors, both 
untreated and treated with chemotherapeutic drugs, as well as in some normal 
tissues (Bell et al. 1985; Daltan et al. 1989; Fojo et al. 1987b; Lai et al. 1989). 
Using slot-blot analysis, levels of MDR1 RNA were high in several types of 
untreated, intrinsically drug-resistant tumors, including those derived from the 
colon, kidney, adrenal gland, liver and pancreas (Goldstein et al. 1989). 
These tumors are known to respond poorly to chemotherapy. It is notable the 
levels of MDR1 RNA and the P-glycoprotein expression were also high in the 
normal tissue of these cancer patients (Fojo et al. 1987b; van der Valk et al. 
1990). A wide variety of untreated cancers, including non-small cell lung 
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cancer，bladder cancer, esophageal carcinoma, gastric carcinoma, head and 
neck cancer, were found to have low levels of MDR1 RNA (Fojo et al. 1987b). 
In normal gastric tissues, MDR1 RNA levels are either negative or only slightly 
elevated (Mizoguchi et al. 1990; Thiebaut et al. 1987). In addition, MDR1 
RNA levels were also increased in some cancers at relapse after 
chemotherapy, including ALL, ANLL, breast cancer, pheochromocytoma (Fojo 
etal. 1987b). 
Several lines of evidence suggest that multi-drug resistance in cancers is due, 
at least in part, to the elevated MDR1 expression. Firstly, when full-length 
cDNA of the human or mouse MDR1 gene are transfected or infected into 
human cells, these cells become multi-drug resistant (Gros et al. 1986; Guild 
et al. 1988; Pastan et al. 1988; Ueda et al. 1987b). Secondly, unselected cell 
lines from tumors, such as renal cell carcinoma with elevated MDR1 RNA 
levels，have a multi-drug-resistant phenotype, and their resistance is reversible 
by use of verapamil and quinidine, which are inhibitors of the multi-drug 
transporter (Fojo et al. 1987a; Gottesman and Pastan 1988). Lastly, the 
expression of MDR1 is associated with poor outcome in patients treated with 
chemotherapy (Chan et al. 1990; Chan et al. 1991 )• Furthermore, analysis of 
MDR1 derivatives of the human epidermoid carcinoma cell line KB has shown 
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that even very low levels of MDR1 gene expression can confer a several fold 
increase in the level of drug resistance, which may be clinically significant 
(Akiyama et al. 1985; Chin et al. 1989; Shen et al. 1986). 
The exact role of MDR1 expression in response to antitumor agents is still 
unknown. In addition, it is not certain whether MDR gene expression can 
predict chemosensitivity and chemotherapeutic response in cancer patients. 
No correlation between MDR1 gene expression and drug sensitivity was found 
in small cell lung cancer (Campling et al. 1997)，and in breast cancer 
(Schneider et al. 2000). So far, few reports have demonstrated a correlation 
between MDR1 gene expression and chemosensitivity testing or 
chemotherapy responsiveness for gastric cancer. It was noted that gastric 
Cancer patients with MDR1 expression did not response to chemotherapy (Yeh 
et al. 1998). Regarding to chemosensitivity testing, only Orita et al. showed 
that high MDR1 expression in gastric cancer correlated with resistance to 
adriamycin treatment (Orita et al.1994). However, Hotta et al. found no 
correlation between expression of P-glycoprotein and the sensitivity for 
adriamycin in cells from gastric tumor patients (Hotta et al. 1999). 
Other studies suggest that P-glycoprotein expression is an indicator for shorter 
survival and poor prognosis in patients with hepatocellular carcinoma (Soini et 
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al. 1996), soft tissue sarcoma (Chan et al. 1991), breast cancer (Schneider et 
al. 1989), and non-small cell lung cancer (Yokoyama et al. 1999). One study 
found MDR mRNA levels to be an indicator of poor prognosis in bladder cancer 
(Clifford et al. 1994). This indirect evidence suggested that P-glycoprotein 
may be associated with chemoresistance (Yokoyama et al. 1999). 
1.3c p53 tumor suppressor gene 
p53 is a tumor suppressor gene that is the most commonly mutated gene in 
human cancer (Steele et al. 1998). Up to 50 percent of the tumors have 
accumulated p53 mutation (Hollstein et al. 1994). p53 was discovered in 
1979 as a result of its binding to the large T antigen of the DNA tumor virus 
SV40 (Lane and Crawford 1979). Subsequent studies have indicated that the 
p53 gene is a tumor suppressor gene (Finlay et al.1989; Lane and Benchimol 
1990). 
The human p53 gene is located on chromosome 17p13 (Isobe et al. 1986). It 
consists of 11 exons and 10 introns that span 2kbp，and encodes a 
phosphoprotein comprising 393 amino acids (Lamb and Crawford 1986). 
Normal p53 protein resides in the nucleus of the cell (Steele et al. 1998). 
Sequencing of the p53 gene in various animals including mammals, birds, 
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amphibians and fishes has revealed five highly conserved domains; domain 1 
in exon 2 (codon 13-19), domain 2 in exon 4 and 5 (codon 117-142), domain 3 
in exon 5 (codon 171-181), and domain 4 in exon 7 (codon 234-258) and 
domain 5 in exon 8 (codon 270-286) (Soussi et al. 1990). 
The protein has an acidic N-terminal region composed of the first 75 amino 
acids (Levine et al. 1991). The first 42 amino acids in the N-terminal domain 
of p53 has been shown to regulate p53 transcriptional transactivation activity 
(Levine 1997; Liu et al. 2001)，and it is a region that interacts with its feedback 
regulator Mdm2 (Oliner et al. 1993). The central core of p53 contains the 
sequence-specific DNA binding region (residues 102-292) (Cho et al. 1994). 
The positively charged carboxyl terminus contains the basic nuclear 
localization sequence (residues 316-325) and oligomerization domain 
(residues 324 to 355) (Levine et al. 1991; Vogelstein and Kinzler 1992). The 
C-terminal 26 amino acids form an open domain composed of nine basic 
amino acid residues that binds to DNA and RNA readily with some sequence 
or structural preferences (Lee et al. 1995). 
p53 plays an important role as the "guardian of the genome" in response to 
endogenous and exogenous mutagens (Forrester et al.1996; Lane 1992). It 
executes cellular checkpoint response after DNA damage or stressful stimuli in 
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both normal and tumor cells (Levine 1997; Moll et al. 1995). Checkpoints 
monitoring DNA damage by p53 operate in late G1 and G2 phases and 
possibly during S phase (Hartwell and Kastan 1994; Murray 1992). The 
exposure of cells to DNA damaging agents, such as ionizing radiation 
(Woloschak et al. 1996), ultraviolet light (Hall et al. 1993)，or chemotherapeutic 
agents (Nabeya et al. 1995) induce high levels of wild type p53 protein. 
Increase in posttranslational stability or in translation of p53 protein results 
high level p53 protein (Nabeya et al. 1995). This leads to cell cycle arrest, 
and allows for DNA repair. 
In addition, p53 is believed to be a regulator of programmed cell death 
(apoptosis) (Bargonetti and Manfredi 2002; Oren 1994). p53 protein has 
been shown to transcriptionally activate pro-apoptotic genes such as bax 
(Miyashita and Reed 1995), and to transcriptionally repress anti-apoptotic 
genes such as bcl-x (Wu et al. 2001) 
Anticancer drugs can induce and enhance chemosensitivity in tumor cell death 
by apoptosis (Barry 1990; Bellamy et al. 1995; Fisher 1994; McDonnell et al. 
1995; Solary et al. 2001). It has been suggested that p53 may enhance 
chemosensitivity by promoting apoptosis via transcription-dependent and 
transcription-independent mechanisms (Weller 1998). In vitro studies 
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indicate that p53 dependent apoptosis modulates the cytotoxicity of 
chemotherapeutic agents such as 5-FU, doxorubicin, and CDDP, and that the 
absence of wild-type p53 function results in cellular resistance to 
chemotherapy in several cell lines including gastric carcinoma (Chang et al. 
1995; Harris 1996). In addition, introduction of the wild-type p53 gene into 
human cancer cell line, which has a homozygous deletion of p53, enhanced 
apoptosis induced by chemotherapy (Fujiwara et al. 1994). Furthermore, 
other studies also showed that cells acquired mutant type p53 are 
chemoresistant because they have lost the ability to induce apoptosis (Lowe et 
al.1993a,1994; Nabeya et al. 1995). Aas et al. suggested that intact p53 
protein may be a prerequisite for the cancer cells to be susceptible to killing by 
the anti-cancer drugs (Aas et al. 1996). Lastly, Yamamoto et al. showed that 
the chemosensitivity of gastrointestinal cancer cell lines with wild-type p53 
tended to be greater than that of cells with mutant p53 (Yamamoto et al. 1999). 
On the other hand, it has also been suggested that p53 may decrease 
chemosensitivity by promoting p27-mediated and p27-indepentdent growth 
arrest, DNA repair, and differentiation, and by enhancing the transcription of 
anti-apoptotic gene (Weller 1998). Wahl et al. found the loss of normal p53 in 
normal human primary cultures confers sensitization to anti-tumor drugs by 
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increasing apoptosis (Wahl et al. 1996). One study showed that disruption of 
p53 sensitizes breast and colon tumor cell lines to CDDP (Fan et al. 1995). 
Other study also suggested cell lines with p53 mutation showed greater 
sensitivity to antitumor drugs, including cisplatin, 5-FU and doxorubicin (Petty 
et al. 1994). p53 defective tumor cells have increased susceptibility to some 
DNA-damaging anticancer drugs (O'Connor and Kohn 1992). Therefore, the 
relationship between the status of p53 and cell response to chemotherapy 
treatment still remains controversial. 
There have been few studies on the relationship between the status of p53 and 
chemosensitivity in gastric carcinoma. Using clinical specimen, Itaya et al. has 
reported a correlation between p53 expression, detected by IHC，and 
chemosensitivity testing using gastric cancer specimen (Itaya et al. 1999). One 
study found p53 protein expression to correlate with chemotherapy response of 
gastric cancer patients (Nakata et al. 1998). In contrast, other study found no 
association between overexpression of p53 and drug resistance of gastric cancer 
patients to 5-FU -based systemic chemotherapy (Yeh et al. 1999). Therefore, 
the relationship between p53 status and chemosensitivity in gastric carcinoma 
also remains to be determined. 
1.4 Chemosensitivity testing 
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1.4a Original of chemosensitivity testing 
Chemosensitivity assays were originally modeled after bacterial sensitivity 
tests. Since the 1950's, in vitro and in vivo assays for the prediction of the 
therapeutic outcome have been developed. They were aimed to provide the 
information that could not only improve the efficacy of the drug treatment, but 
also avoid unnecessary side effects of ineffective drugs. Chemosensitivity 
testing can be done either in vitro or in vivo. In vivo, subrenal capsule assay 
(in normal mice) was commonly used and it was the only in vivo assay 
showing correlation to the clinical response (Griffin et al. 1983; Slee et al. 
1985). However, the techniques required for accurate determination of this 
method demanded great skills and experience (Edelstein 1986). On the other 
Hand, a number of in vitro tests are available, most of them fall into two groups: 
the non-clonogenic assay and clonogenic assay. 
1.4b Non-clonogenic assay 
The non-clonogenic assays evaluate chemosensitivity by either assessment 
for cell viability or cellular metabolic activity. Differential staining cytotoxicity 
(Disc) assay (Weisenthal and Kern 1991) is an example of non-clonogenic 
assay that measures cell viability. It uses a morphological end point to 
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determine the chemosensitivity. The living cells in the assay exclude the 
green dye and thus they appear clear. In contrast, the dead cells appear 
bright green. The morphology of cells also allows one to determine different 
effects on tumor cells versus non-tumor cells. This assay is of short duration 
and has high evaluation efficiency (Bird et al. 1986) and it was claimed that the 
in vitro response correlated with patients' drug sensitivities (Bird et al. 1988). 
Nevertheless, a skilled technician is required to distinguish the tumor and 
normal cells and to count the living and dead tumor cells. Thus, subjective 
interpretation is the major factor that may affect the result. Moreover, the 
assay has limited application to solid tumor although the experience with 
hematological neoplasm is better (Bellamy 1992). 
The adenosine triphosphate inhibition test evaluates drug sensitivity by 
comparing intracellular metabolic activity in the form of adenosine triphosphate 
(ATP), the primary energy source of living cells, in the treated and control cells 
(Kangas et al. 1984; Kuzmits et al. 1986). The total cellular proliferation is 
detected by the light generated with a luciferin-luciferase reagent in a 
luminometer. Although this assay yields result in a week and requires few 
cells, the usefulness in clinical setting has yet to be determined (Bellmey 
1992). 
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Similar to the ATP assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay (Mosmann 1983) also measures cellular metabolic 
activity to evaluate the drug sensitivity. However, a yellow tetrazolium salt is 
used instead. This compound is metabolized to a blue-pruple formazan dye 
product through the action of a mitochondrial succinic dehydrogenase. The 
UV absorbance of the formazan crystals is measured spectrophotometrically, 
and it correlates with the metabolic activity that in turn reflects the number of 
viable cells in the sample. The most important advantages of this method are 
its speed, technical simplicity, reproducibility, accurate and high sensitivity for 
measuring the chemosensitivity of single agents and drug combinations 
(Andreotti et al. 1995, Kangas et al. 1984，Mosmann 1983). Cumulative data 
have showed MTT assay is the most frequently used chemosensitivity test 
performed in Japan (Do et al. 2000). However, the short incubation period 
may result in underestimation of the efficacy of some chemotherapeutic agents 
(Fujita et al. 1998). 
1.4c Clonogenic assay 
The last major type of in vitro chemosensitivity test is the clonogenic assay or 
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so-called "stem cell assay", which was described by Hamburger and Salmon 
(Hamburger and Salmon 1977). In this assay, single cell suspensions of tumor 
cells are exposed to anti-tumor drugs. They are plated in soft agar up to 14 days. 
The soft agar allows tumor cells to grow into colonies; other normal cells are 
inhibited. The sensitivity is estimated by counting survival clones of cells. The 
colonies formed in this assay assume to represent the true "stem cell", which has 
unlimited division potential. Therefore, this assay does not take non-proliferative 
cells into account. However, this assay has many drawbacks. Firstly, the 
evaluation rate of this assay is low partly because large number of cells is 
required (Bellamy 1992; Nguyen et al. 1991). Secondly, the duration required is 
long (Weisenthal and Lippman 1985). Lastly, the presence of clumping artifacts 
complicates the counting of clones of cells (Brown and Markman 1996). In 
addition, the cells may not be truly the stem cells (Weisenthal and Lippman 1985). 
Thus, the usefulness in predicting the chemotherapy responsiveness is limited. 
None of the chemosensitivity tests has an overwhelming superiority over the 
others. The chemosensitivity tests are not standardized for gastric carcinoma. 
Depending on the experimental conditions，different chemotherapy tests have 
been adopted. A well-designed chemosensitivity test standardized for the 
gastric cancer is needed. 
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2. AIM OF MY STUDY 
The objectives of my study are the following: 
1. To establish a chemosensitivity test for short-term culture primary gastric 
carci � oma. 
2. To optimize the chemosensitivity testing conditions. 
3. To perform chemosensitivity test on primary gastric carcinomas using a selection 
of drugs. 
4. Determine p53 expression in gastric carcinoma. 
5. Screen for p53 mutation in these samples. 
Compare the MDR1 gene expression in the normal and tumor. 
入 To investigate any correlation between chemosensitivity of the tumors and MDR1 
gene expression. 
To investigate any correlation between chemosensitivity of the tumors and p53 
expression and mutation. 
To investigate any correlation between the MDR1 gene expression and p53 
�expression and mutation. 
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3 MATERIALS AND METHODS 
3.1 Patients 
Between year 1999 and year 2002, 31 patients with diagnosed of gastric 
adenocarcinoma were recruited into this study. All of them underwent surgical 
resection of carcinoma at Prince of Wales Hospital, Hong Kong. Of these 
patients, 18 were male, and 13 were female. The mean and the median age of 
the patients were both 61 years. Cases were selected for chemosensitivity 
testing and subsequent molecular analysis based on tissue availability. Thus 
only cases with large fresh tumor tissue (sufficient to allow at least 2cm diameter 
X3mm thick piece of tumor to be removed without jeopardizing histopathologic 
diagnosis) were recruited. The gastrectomies were examined macroscopically 
and tissue sampled for histology. The blocks sampled included resection 
margins，sampling of tumor, residual benign body and antral mucosa, and lymph 
nodes. Tissue immediately adjoining the sampled area of the tumor and normal 
tissue for the chemosensitivity experiments was always included in histologic 
sampling to ensure that they indeed contained tumor or normal tissue. The 
tissue was fixed in 10% buffered formalin and routinely processed for paraffin 
embedding and sectioning. The hematoxylin-eosin stained paraffin sections 
were examined by a qualified pathologist (W Y Chan). The tumors were 
histologically classified according to the Lauren classification (Lauren 1965). 
Tumor stage was based on the TNM tumor classification system. Detailed 
information of the cases is listed in appendix 3. 
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3.2 Tumor collection and handling procedure 
3.2a Large tumor tissue from gastrectomy 
Tumor and normal gastric tissue specimens were sampled from the 
gastrectemies immediately after surgery. They were submerged fresh in 
phosphate buffered saline (PBS) (Sigma, St 丄ouis，MO, USA) until 
disaggregation. Tumor was subjected to disaggregation by combination of 
mechanical and enzymatic methods. They were first washed six times with PBS 
containing 200 units (U)/ml penicillin/ 200|Lig/ml streptomycin (P/S) (Gibco, Grand 
Island，NY, USA) and 0.25|Lig/ml fungizone (Gibco, Grand Island, NY, USA). 
Tumor was then finely minced with razor blade to approximately 1mm in size in a 
100mm culture plate. About 15ml "enzymatic dissociation solution", comprising 
1.0mg/ml collagenase type IV (Gibco, Grand Island, NY, USA), 0.25mg/ml 
hyaluronidase (Gibco, Grand Island, NY, USA), 0.4mg/ml DNase-1 (Boehringer 
Mannheim, Basel, Switzerland), 100U/ml penicillin/ 100|Lig/ml streptomycin, and 
0.25^g/ml fungizone in Dulbecco's Modification of Eagle's Medium (DMEM) 
(Gibco, Grand Island, NY, USA), was added to the minced tumor. They were 
incubated for 1.5 hr at 37�C in an atmosphere of 5% CO2. Single cell suspension 
was filtered through the 100|Lim nylon mesh (Sigma, St. Louis, MO, USA). Tumor 
clumps were collected and washed with complete medium consisting DMEM, 
15% Fetal Bovine Serum (FBS) (Gibco, Grand Island, NY, USA), 100U/ml 
"‘penicill in/ 100|Lig/ml streptomycin and 0.25|Lig/ml fungizone. After the tumor 
clumps were spun down and the supernatant was disposed, a portion of tumor 
clumps was cultured and maintained in complete medium in 25-cm^ culture flask 
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at 37°C in a 5 % C O 2 atmosphere，and remaining tumor clumps were stored in 
vials containing F B S with 1 0 % dimethyl sulfoxide ( D M S O ) (Sigma, St. Louis, M O , 
U S A ) in liquid nitrogen. Single cell suspension w a s further enriched by 1 0 0 % 
and 7 5 % Ficoll (Amersham Pharmacia Biotech A B , S w e d e n ) gradients as 
described in literature (Yamaue 1992). Single tumor cells were snapped frozen 
and stored in liquid nitrogen. 
20 cases were collected and cultured immediately after disaggregation 
procedures. 11 cases were previously disaggregated and stored at liquid 
nitrogen tank. These archival tumor clumps were thawed at room temperature 
and then cultured as the fresh cases. 
3.2b Pseudo-biopsies 
In six cases, pseudo-biopsies of the tumor were removed from the gastrectomy 
prior to sampling of the main tumor bulk for the above procedures. These 
consisted of 6 pieces of 2 m m X 2 m m X 2 m m tumor tissue sampled from the 
mucosal aspect at the edges of the ulcerated tumor, mimicking endoscopic 
biopsies. These biopsies were not filtered through the nylon m e s h . They were 
w a s h e d with complete m e d i u m after enzymatic digestion, and were cultured for 6 
w e e k s . . 
V 
At the end of the culture period, to ensure that the cultured cells were indeed 
, t u m o r cells rather than fibroblasts, immunostaining for cytokeratin w a s done. 
The tests were performed only if the cultured cells showed positive staining. 
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3.3 Chemosensitivity testing 
3.3a Cell Plating 
W h e n the tumors in culture flask were confluent, they were trypsinized. Total 
number of cells w a s counted by hemacytometer (Sigma, St. Louis, M O ) . The 
cells were diluted to a concentration of 1000 cells/90|al of complete medium. D u e 
to insufficient tumor cells grown in culture, not all tumor samples were subjected 
to the full panel of drug tests. The drug tests done on the specimens are listed in 
appendix 4. 
For each single drug test, 6 different concentrations in 4 replicates were tested 
on each tumor. Four replicates of cells with no drug added were included as 
controls. O n e thousand tumor cells were dispensed into each replicate well of a 
96-well clear polystyrene microtiter plate (Nunclon) (Roskilde, Denmark). 
Another four replicates were designated to check for background contamination 
and to each of these 90 I complete medium without tumor cells w a s added. 
—no drug Medium 
Cone 1 Cone 2 Cone 3 Cone 4 Cone 5 C o n e 6 
Rep1 only 
V 
Conc1 to Conc6 = the 6 different drug concentrations 
Rep1 to R e p 4 = The 4 replicates of test samples 
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3.3b Drug testing 
Drugs were prepared in the following concentrations in complete medium: 
5-fluorouracil (Sigma, U S A ) at 5000 |Lig/ml, 1250 ^ig/ml, 312.5 ing/ml, 
78.125 |Lig/ml, 19.53 |Lig/ml, and 4.88 |ag/ml. 
Adriamycin (Pharmacia & Upjoin，Italy) at 200 ^g/ml, 40 ^ig/ml, 8 fig/ml, 
1.6 |Lig/ml, 0.32 ^ig/ml, and 0.064 |ag/ml. 
Cisplatin at 100 i^g/ml, 25 |ag/ml, 6.25 |Lig/ml, 1.56 ^ig/ml, 0.39 ing/ml，and 
0.097 i^g/ml. 
Daunomycin (Pharmacia & Upjoin，Italy) at 200 ng/ml, 40 ^ig/ml, 8 [ng/ml, 
1.6 jLig/ml, 0.32 |ig/ml, and 0.064 |ng/ml. 
Epuirbicin (Pharmacia & Upjoin，Italy) at 2000 ng/ml, 500 ^ig/ml, 125 i^g/ml, 
31.25 |Lig/ml, 7.8125 |Lig/ml, and 1.973 ^ig/ml. 
Drugs were added on the following three consecutive days of the experiment. 
D a y 1: Plating of cells. 
D a y 2: 10|j| of prepared drugs w a s then added to the wells (the final 
concentration = 1/10 of the prepared drugs). 
For the controls, 10 I of complete m e d i u m w a s added. 
D a y 3: the solution in the wells w a s drawn out, and fresh 90 I of complete 
�d i u m and 10 I of prepared drug were added to the wells. For the controls, 
10 I of complete m e d i u m w a s added. 
D a y 4: Repeat procedures of D a y 2. 
D a y 5: 20 I of M T S solution (CellTiter 96 Aqueous O n e Solution Cell 
Proliferation Assay, Promega, Madison, W l , U S A ) w a s added to each well. After 
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4 hours of incubation at 37 the optical density (OD) w a s measured with a 
spectrophotometer at the wavelength of 4 9 0 n m with the reference wavelength at 
6 9 0 n m . 
Pseudo-biopsies were treated in similar procedures as described above for the 
tumor chemosensitivity testing. The drug tests on the tumors and their 
respective pseudo-biopsies were done simultaneously. 
3.4 Chemosensitivity analysis 
The tumors and pseudo-biopsies were analyzed for their relative 
chemosensitivity. The relative percentage of cell growth (RG) w a s calculated 
with respect to the control using the formula: 
R G = (A-B)/(C-B) X 1 0 0 % 
A = O D of the samples 
B = average O D of the background 
C = average O D of the control 
The data were then converted to the number of cells present in the samples with 
respect to the control by the following formula: 
1 0 0 0 X ( 1 0 Q - R G ) % . 
V 
The data (number of cells respected to the control) obtained from the calculation 
were then entered to a Probit program in S P S S version 10.0 (Chicago, Illinois, 
USA). The S P S S program used all 32 entries to plot a curve and from it 
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calculated the final IC50 (the concentration of drug required to achieve 5 0 % 
inhibition of cell growth under the above experimental conditions) for each drug 
test in each tumor samples. 
3.5 Conformational sensitive gel electrophoresis analysis (CSGE) and single 
strand conformational polymorphism (SSCP) 
3.5a Preparation of genomic D N A 
Genomic D N A w a s prepared from tumor cells stored in liquid nitrogen. D N A from 
the norma丨 gastric tissue of the s a m e patient w a s also included as a negative 
control in the C S G E and S S C P studies. The normal and tumor tissue samples 
were subjected to digestion in S T E , composed of 5 M N a C b , 2 M Tris and 0.1 M 
E D T A at p H 7.4, together with 0.5% sodium dodecyl sulfate (SDS) and 10(Vg/ml 
proteinase K (Sigma, St. Louis, U S A ) overnight at 55°C on a rotating wheel oven. 
D N A extraction w a s performed using phenol chloroform premixed with isoamyl 
alcohol (25:24:1) (Ammsco’ Solon, Ohio, USA). 
D N A w a s precipitated with one-tenth volume of 3 M a m m o n i u m acetate and 2 
volumes of 1 0 0 % ice-cold ethanol. It w a s then washed with 7 0 % ethanol, air 
dried and redissolved in milliQ water. 
3.5b P G R condition for C S G E analysis 
. . P C R amplifications of exons 4’ 5 /6, 7 and 8/9 of the p53 gene were carried out. 
The primer sequences and their product sizes are listed in Appendix 5. P G R w a s 
performed in 25^1 reaction mixture containing 300ng of D N A , of 10X P G R 
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buffer, 2.5|liI of 2 5 m M MgCl2, 2.5}J of 2 . 5 m M of forward and reverse primers, 
2.5|LII of 2 m M of d A T P , d T T P , d C T P , and d G T P , and 0.15|LII (5 units/FJ) of 
AmpliTaq Gold polymerase (PE Applied Biosystems, Branchburg, N e w Jersey, 
USA). P G R w a s carried out on a PTC-100 programmable thermal controller (MJ 
Research, Inc., Waltham, Massachusetts, USA). T h e P G R w a s initiated at 95°C 
for 10 mins for denaturation. It w a s then followed by 40 cycles consisted 40 sec 
at 9 4 � C ’ 40 sec at 55 °C, and 40 sec at 72 °C. The final product w a s extended 
for 10 mins at 72 °C. 
3.5c Scanning P G R products by C S G E 
For heteroduplex analysis by C S G E , P G R products were electrophoresed in a 1-
m m thick gel set in a standard long glass plate with 50-well c o m b s . T h e gel w a s 
prepared with 1 5 % polyacrylamide, 99:1 ratio of acrylamide to N，N’-
diacryloylpiperazine (Sigma, Oakville, O N , Canada), 1 0 % ethylene glycol 
(Sigma), 1 5 % formamide (USB, Cleveland, O H , USA), 0.1% a m m o n i u m 
persulfate (USB, Cleveland, O H , USA), and 0.07% /V,/\/,A/'A/-tetramethyl-
ethylenediamine in 0.5X T T E buffer m a d e up of 4 4 . 4 m M Tris/14.5mM 
Taurine/0.1mM E D T A buffer, p H 9.0. 5^1 of P G R products were first mixed with 
1|Lil of 6 X stock loading buffer, which w a s m a d e up of 0.25% bromophenol blue, 
V. 
0.25% xylene cyanol FF，and 3 0 % glycerol in water. T h e y were then denatured 
for 5 mins at 95。C，and left at room temperature for 30 mins before loading. T h e 
gel w a s pre-electrophoresed for 30 mins at 2 5 W using 0.5X T T E buffer as the 
electrode buffer. T h e samples were then run at 4 0 W for 5 hours at room 
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temperature. After electrophoresis, the gel w a s stained with ethidium bromide for 
10 min. The bands were visualized on a U V transilluminator. A n aberrantly 
migrating band indicates the presence of mutation or polymorphism. 
3.5d P G R condition for S S C P analysis 
Nested P G R w a s carried out to scan for mutation in exon 7 of p53 gene in the 
tumor samples. Both the outer and inner pairs of primer sequences together with 
their product sizes were listed in Appendix 6. The outer region w a s first amplified 
by non-radioactive method. Similar P G R procedures as described above were 
conducted except that the annealing temperature increased to 58 °C and total 
amplification cycles w a s 30. The products were then re-amplified by the inner 
pair of primers using the s a m e condition for outer region except that the 
amplification cycles were reduced to 12. The products were run on 1 0 % 
acrylamide (29:1’ acrylamide:bis ) gel. The expected size 177bp product w a s cut 
out and eluted with 20|il milliQ water at 55 °C in a rotor oven for 2 hours. 2 fj of 
the D N A product w a s then re-amplified using the s a m e inner pair of primers for 
10 cycles by radioactive method, in which an additional 0.1 ^il of [alpha-^^P] d C T P 
(3000 Ci/mmol) w a s added to each P G R reaction mixture. Other components of 
the P G R reaction mixture were s a m e as above. 
- 3 . 5 e Scanning P G R products by S S C P 
To scan for mutation by S S C P , 3|al of product w a s added to 1 i^l of loading dye 
m a d e of 9 5 % formamide’ 0.1% xylene cyanol, 0.1% bromophenol buffer, and 
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0.01M E D T A (pH 8.0). The samples were then denatured by heating to 95 °C for 
5 minutes to single-stranded D N A , chilled on ice and loaded immediately to wells 
of a 80 cm-length of a 6 % nondenaturing polyacrylamide gel (49:1’ acrylamide: 
bis) in 0.5X T B E with 1 0 % glycerol. Using 0.5X T B E as the electrode buffer, the 
gel electrophoresed for 16 hours at room temperature at 3 watts constant power. 
S S C P analysis w a s also performed with M D E gel ( B M A , Rockland, M E , U S A ) 
and the running condition w a s the same. 
Gels were then exposed to X-ray film at -80 °C with intensifying screens for 3 
days before autoradiographic development. Aberrantly migrated bands 
additional to the normal p53 banding pattern indicated the presence of mutations. 
3.6 Reverse transcription-polymerase chain reaction (RT-PCR) for multi-drug 
drug resistance (MDR1) gene 
3.6a Isolation of R N A 
A total of 25 cases were analyzed for their MDR1 expression. Total R N A w a s 
extracted from the digested tumor tissues and their adjacent normal tissues using 
TRIzol reagent (Gibco B R L , Grand Island, N Y , USA), which is modified from the 
original method of Chomczynski and Sacchi (Chomczynski et al 1987). The 
normal and tumor tissues of case 2，3，and 5 to 13 were stored at -80°C, and the 
remaining tissues (case 14-27) were stored in liquid nitrogen. In addition, R N A 
.extracted from h u m a n astrocytoma cell line U 3 7 3 - M G w a s included as positive 
control in this study. Briefly, the tissues were pulverized and lyzed in TRIzol 
(Gibco, USA), and R N A w a s extracted followed the manufacturer's protocol. 
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R N A w a s dissolved in diethyl pyrocarbonate (DEPC)-treated water. R N A yield 
and purity were checked by spectrophotometer assessment at 2 6 0 n m and 
2 8 0 n m . 
3.6b c D N A synthesis 
First-strand c D N A w a s synthesized from total R N A by reverse transcription using 
oligo (dT) that binds to the 3，poly-A tail of the R N A . lOOOng (2^1) of each total 
R N A sample and (Vg/^il) of oligo d T (Amersham Pharmacia, Piscataway, NJ, 
U S A ) were added to 12|il of DEPC-treated water. The sample w a s heated to 
70。C for 5 minutes. The remainder 10…of reaction mixture consisting 5…of 5 X 
Moloney Murine Leukemia Virus Reverse Transcriptase, R N A s e H Minus, Point 
Mutant ( M - M L V R T ) reaction buffer (Promega, Madison, USA), 1 .25|liI of 1 0 m M 
d A T P， d C T P , d G T P , and d T T P (Amersham Pharmacia, Piscataway, NJ, USA), 
1|Lil (200 units) of M - M L V R T (Promega, Madison, USA), and 2.75|^l of D E P C -
treated water w a s then added to the R N A sample to m a k e up the final volume of 
25|LII reaction mixture. The mixture w a s then heated to 42。C for 60 minutes. 
Afterward, c D N A were stored at -20°C until use. 
3.6c P G R primers 
P C R w a s carried out with the c D N A . The MDR1 and P2-microglobulin (P2-m) 
primers chosen were those used by N o o n a n et al (Noonan et al 1990). T h e 20-
m e r primers were synthesized by Invitrogen (Carlsbad, C A , USA). T h e 
sequences of both pairs primer are listed in the Appendix 7. Both the MDR1 and 
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Ih-m primers span an intron to control against contamination by amplification of 
genomic D N A sequences. The primers yielded products of 167 base pairs for 
MDR1 and 120 base pairs for j32-m. 
3.6d Optimalization of P G R condition for MDR1 gene expression 
A n initial range-finding experiment and kinetic analysis were performed to 
determine the optimal cycle number for P G R amplification in which the P G R 
product w a s in the logarithmic phase. The procedures were as described in Lee 
et al. (Lee et al. 1996). Briefly, 2^1 of c D N A from U 3 7 3 M G , a h u m a n 
glioblastoma cell line w a s P G R amplified. U373 M G cell line is known to have 
high, intrinsic M D R 1 expression (Walther et al. 1995). The P G R reaction w a s 
carried out in a final volume of 20|J containing 2^1 of c D N A , 0.2fil (1 unit) of 
AmpliTaq Gold polymerase (PE Applied Biosystems, Branchburg, N e w Jersey, 
USA), of 10X P G R buffer, 2 i^l of 2 5 m M MgCIs, 2|LII of 2 . 5 m M d N T P 
(Amersham Pharmacia, Piscataway, NJ, U S A ) and 2^1 of 2 m M of each sense 
and antisense primer. The reaction mixture w a s overlaid with light mineral oil. 
The P G R w a s performed on a PTC-100 programmable thermal controller (MJ 
Research, Inc., Waltham, Massachusetts,USA). For j32-m gene, the reaction w a s 
first carried out at 95°C for 10 minutes for denaturation, and then followed by 30 
cycles consisting 94°C for 30 seconds, 58°C for 30 seconds, and 72。C for 30 
seconds. Finally, the reaction w a s extended at 72°C for 10 minutes. P G R w a s 
carried out for 20，25，27，30，32，35，and 40 cycles. For the MDR1 gene, similar 
procedures were also performed on U 3 7 3 M G cell line except annealing 
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temperature w a s raised from 58°C to 60°C. The cell line had logarithmic phase 
of amplification of p2-microglobulin—specific product similar to that of M D F n -
specific product. The optimal cycling number for P G R w a s determined to be 32. 
3.6e P G R of j32-m gene 
First, P G R w a s carried out in gastric tumor samples using the j32-m primer. j32-m 
w a s an internal control for the quality and amount of template in each reaction. 
Similar procedures as described above were carried out except that P G R w a s 
run for 32 cycles. 10|J of P G R products w a s run on 2 % agarose gel. The 
intensity w a s then analyzed and adjustment w a s m a d e to normalize the P G R 
product. 
3.6f P G R of MDR1 gene and analysis of its expression 
To determine the MDR1 expression in gastric tumor samples, P G R w a s carried 
out for 32 cycles under the conditions described above for MDR1 gene. 
product of the P G R reaction w a s electrophoresed on 2 % agarose. The tumor 
and normal samples of the s a m e case were run side by side for comparison. 
W h e n a visible band w a s detected in the tumor sample and no band appeared in 
the normal sample, or a stronger band appeared in the tumor sample compared 
to a weaker band in the normal sample, MDR1 gene w a s interpreted as 
overexpressed and positive. The result w a s considered negative w h e n both 
tumor and its normal samples showed no band. 
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3.7 Immunohistochemistry 
3.7a 丨mmunostaining for D O - 7 
Formalin fixed, paraffin e m b e d d e d tissue sections from the tumors were 
analyzed immunohistochemically for altered patterns of p53 protein expression 
using avidin-biotin technique. Sections were cut at 5|am thickness, and mounted 
on slides coated with aminopropyltriethoxysilane (APES). The slides were dried 
overnight at 55°C. The sections were deparaffinized in xylene and rehydrated in 
a decreasing concentrations of ethanol, (100%-> 9 5 % -> 70%). Afterward, the 
process of antigen retrieve w a s carried out by placing the tissue slides in a 
plastic container containing citric buffer and heating them for 3.5 minutes in a 
microwave processor at 850 watts, followed by ten minutes at 170 watts. After 
the microwave processing, the slides were left at room temperature for 30 
minutes. The process of blocking endogeneous enzymes w a s then performed by 
incubating the tissue slides with 0.03% hydrogen peroxide in Tris-buffered saline 
(TBS) for fifteen minutes. Slides were then washed 3 times with T B S . The 
Avidine-Biotin complex (ABC) method w a s employed. Sections were covered 
with 5 % normal rabbit serum ( D A K O , Carpenteria, C A , U S A ) in T B S for 15 
minutes to reduce nonspecific staining. They were then incubated in a 1:100 
dilution of primary antibody p53 D O - 7 ( D A K O , Carpenteria, C A , U S A ) with 0.3% 
- b o v i n e serum albumin (BSA) at room temperature for 2 hours. The sections 
were washed with T B S , and incubated with 1:200 biotinylated rabbit anti-mouse 
immunoglobulin ( D A K O , Carpenteria, C A , U S A ) at room temperature for 45 
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minutes. Again, the sections were washed with T B S , and incubated with 1:400 
streptavidin horseradish peroxidase ( H R P ) conjugate (Zymed, S a n Francisco, 
C A， U S A ) at room temperature for 30 minutes. The antibody w a s visualized with 
3，3，-diaminobenzidine tetrahydrochloride (DAB) with 0.03% hydrogen peroxide 
for 10 minutes. Tissue sections were counterstained with hematoxylin, 
dehydrated with a graded ethanol series (70%, 9 5 % and 100%), and mounted 
under a coverslip. Negative controls were sections of the s a m e tumors without 
adding primary antibody. 
3.7b Immunohistochemistochemical analysis of p53 protein expression 
The tumors slides were examined for p53 protein immunoreactivity. Positive p53 
protein immuno-reaction w a s represented by nuclear brown-colored staining. 
Level of immunoreactivity w a s expressed as the percentage of tumor cells with 
P 5 3 protein positivity. For analysis, tumors were classified into following 
categories: 
1. - negative ( no positive nuclei staining) 
2. + low level (<1/3 of tumor cells showing positive nuclei staining) 
3. ++ m e d i u m level (>1/3 but <2/3 of tumor cells with positive nuclei staining) 
4. +++ high level (>2/3 of the tumor cells with positive nuclei staining) 
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3.8 Statistics 
Fisher's exact test and student f-test were applied. T h e level of significance w a s 
set at p< 0.05. 
59 
4. RESULTS 
4.1 Chemosensitivity testing 
4.1a Tests completed 
A total of 31 tumor specimens were cultured for 6 weeks to produce sufficient 
cells for chemosensitivity tests to be performed. However, not all samples had 
yielded sufficient cells for the full panel of drug tests. The drug tests done on 
individual cases are shown in Appendix 3. Twenty one cases had completed all 
five drug tests. Three cases had completed four drug tests and six cases had 
completed three drug tests. However, one case had completed only two drug 
tests. 
The yield of the culture w a s similar for the biopsies and their corresponding 
large tumor specimens, indicating that the rate of proliferation is related to 
intrinsic properties of the tumor. 
4.1b N u m b e r of cases tested for each drug 
A total of 28 cases were tested with adriamycin. Twenty seven cases were 
tested with 5-fluorouracil and daunorubicin. Twenty six cases completed 
chemosensitivity testing for cisplatin. However, chemosensitivity testing on 
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epirubicin w a s only performed on 25 cases. 
4.1c O D reading of the background samples 
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It has previously reported high background w a s observed in the m e d i u m 
containing serum observed high background (with only the complete medium) 
(Denizot and Lang 1986). Therefore, all the background readings were checked 
after 4 hours incubation with the M T S agent. All the readings were between 0.2-
0.3. These values were in the expected range as suggested by the manufacturer. 
4.1d Dose-dependent response curve 
Using the S P S S program, the IC50 w a s calculated for each test for each tumor 
sample. Besides, the IC50 can also be calculated by plotting the relative 
percentage of cell growth with respect to the control against the log of the dose 
concentration. The best fit line drawn from six data points can then used to 
determine individual IC50. All of the tumors tested responded in a dose 
dependent manner. Examples of representative drug dose dependent tumor 
growth are shown in Figure 1. 
4.1 e Unique IC50 for each tumor in each drug test 
Each tumor sample showed an individual drug resistance and sensitivity pattern. 
N o two tumors had identical ICso. 
4.1f W i d e distribution of IC50 for anti-tumor drugs 
. T h e tumors showed a large variation in their IC50 for all five drugs. 
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For 5-FU, the IC50 of the archival cases showed a range that w a s significant 
different from the fresh cases in the 5-FU treatment (non-parametric t- test, p= 
0.020181). W h e n all tumors were plotted on a single graph, the results showed 
a bimodal distribution. The cases would be separated into 2 groups, the 
archival and fresh, w h e n the distribution of the ICso w a s analyzed. All archival 
cases and fresh cases responded in a dose-dependent manner. 
The IC50 of the two groups were not significant different for the four remaining 
drugs, thus, they were considered as one group. 
T h e m e a n of ICso for 5-fluorouracil w a s 134 |^g/ml in the archival group with a 
m a x i m u m IC50 of 418 ing/ml, and a minimum IC50 of 5.3 ^ g/ml. T h e m e a n of 
•Csoin the fresh samples w a s 0.06 |ag/ml with a m a x i m u m IC50 of 0.1|ag/ml, and 
a m i n i m u m IC50 of 0.01|Lig/ml. The m e a n IC50 for adriamycin w a s 0.8 |ag/ml and 
1950 ranged from the lowest 0.00002 |ag/ml to the highest 61 pg/ml. T h e tumor 
samples had a m e a n IC50 of 17 ^ig/ml for daunombicin. T h e m a x i m u m ICso w a s 
430 |Lig/ml and minimum IC50 w a s 0.0008 lug/ml. For epirubicin, the m e a n IC50 
w a s found to be 28.6 jiig/ml，having 486 ^ig/ml as the m a x i m u m IC50 and 0.01 
l^g/ml as the m i n i m u m IC50. Lastly, the tumor samples had a m e a n IC50 of 1 . 2 
、l^g/ml for cisplatin, having 8.2 ^ig/ml as the m a x i m u m IC50 and 0.0034 ng/ml as 
the minimum IC50. A large fold of variation is found in all drug tests with 
daunombicin showing the greatest variation fold (5X 10^) while the fresh sample 
of 5-FU showing the lowest variation fold (10). 
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Figure 2 shows graphs representing all ICso’ given in pg/ml on logarithmic scale 
in order to avoid negative number and to fit closer on the graph. The 
distribution of ICsoof daunorubicin’ epirubicin, and 5-FU in the fresh group were 
close to a normal curve. For 5-FU in the archival group and the remaining three 
drugs, cisplatin, adriamycin, the curves were slightly skewed. 
A table summarizing the statistical analysis of the IC50 is shown in Appendix 8. 
4.1g Chemosensitivity and tumor histologic type 
M e a n (standard deviation) of log ICsoand tumor type 
Intestinal type Diffuse type 
5-fluorouracil (archive) 5.07 (0.35) 3.73 * only one case 
5-fluorouracil (fresh) 1.70 (0.27) 1.67 (0.23) 
Adriamycin 2.95 (1.39) 3.14 (0.94) 
Cisplatin 3.3 (1.06) 3.14 (0.79) 
•• Daunorubicin 3.72 (1.01) 3.07 (1.31) 
Epirubicin 4.47 (1.10) 3.71 (1.49) 
There is no statistically significant difference between the log IC50 of the diffuse 
and intestinal type tumors. 
V. 
4.1h Correlation of 丨〇50 with tumor stage 
Figure 3 shows the distribution of IC50 (in pg/ml on logarithmic scale) of the 
cases according to the tumor stage. N o correlation between tumor stage and 
IC50 w a s identified. 
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4.2 Immunohistochemical staining ofp53 protein (DO-7) 
4.2a P53 protein accumulation in samples 
All 31 cases were studied for p53 expression using DO-7 monoclonal antibodies. 
Of these, 20 cases (65%) showed p53 expression. 6 of them showed low level 
of expression of p53 (< 1/3), 4 showed intermediate level (>1/3 but <2/3) of 
expression, and 10 high expression (>2/3). 
Twelve cases out of 20 cases (60%) with Lauren's intestinal type and seven out 
of 10 cases (70%) with the diffuse type gastric cancer had positive nuclear 
staining. The difference w a s not statistically significant. And, one out of the 
three cases (33%) with mixed type of gastric carcinoma w a s immunopositive. 
A table summarizing the result is shown Appendix 9. Representative IHC results 
are shown in Figure 4. N o significant correlation is found between any of the 
clinicopathological parameters (tumor stage, lymph node status, histologic type, 
age and sex of patients) and p53 expression. 
4.2b Correlation of p53 IHC expression and chemosensitivity 
The ICso.of the tumors positive and negative for p53 expression did not differ 
V 
significantly for 5-FU, adriamycin, daunorubicin and epirubicin. However, for 
cisplatin, the tumors with p53 expression had significantly higher IC50 than those 
which were negative (non-parametric t-test p= 0.025). 
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4.3 SSCP and CSGE 
4.3a Detection of abnormal band m o v e m e n t 
T w o cases were not analyzed for genetic alteration by S S C P and C S G E due to 
the insufficient tissue. Out of the 29 cases that had been studied for genetic 
alterations, 15 (53.6%) of them showed band shift either by S S C P or C S G E 
between exons 4 and 9. Figure 5 shows the band shift pattern in representative 
cases. A table summarizing the clinical variables and genetic alternation is 
s h o w n in Appendix 10. 
p 5 3 mutations were noted in 10/18 (55.6%) of the intestinal type of gastric cancer 
showed whilst 5/9 (55.6%) cases of diffuse type cancer. T h e two cases with 
mixed type gastric carcinoma were negative. 
N o significant correlation w a s found between p53 mutation and the various 
clinicopathological parameters (tumor stage, lymph node status, histologic type, 
age and sex of patients). 
Fifteen of the 29 (51.7%) examined cases were found to have aberrant migration 
pattern, and a s u m of 18 band shifts w a s found in these exons. Eleven of the 18 
were located in exon 4. T w o band shifts were located in exon 5/6 and the 
remaining 5 band shifts were found in exon 8/9. There were three cases with 
...p53 gene alternation in two sites. T w o samples had aberrant migration patterns 
for both exon 4 and exon 8/9，and one samples had abnormality in exon 4 and 
exon 5/6. S S C P analysis w a s further carried out to e x a m the two cases (cases 4 
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and 25) showing band shifts in exon 5/6 by C S G E using two pairs of primers that 
span exon 5 and exon 6 separately. S S C P confirmed the aberrant migration 
pattern found in C S G E . Band shift w a s detected in case 4 only by exon 5 primer 
while band shift w a s detected only by exon 6 primer in case 25. The gene 
abnormality for case 4 w a s located in exon 5 and for case 25 in exon 6. 
Figure 6 shows S S C P result for exon 6. 
A s u m m a r y of the distribution of p53 mutations analysis is listed in Appendix 11. 
N o abnormal band migration pattern w a s detected in exon 7 by both S S C P and 
C S G E using the s a m e pair of primer, indicating that abnormality of exon 7 w a s 
absent in these gastric cancer samples. 
Of the nine cases of diffuse type tumor, four had mutations of exon 4 and two in 
exons 8/9. In contrast, of 18 intestinal type tumors seven had mutations in exon 
4 and three had mutations of exons 8/9. The differences were not statistically 
significant. 
4.3b Correlation of p53 mutations with chemosensitivity 
N o significant difference w a s found between ICso of the tumors with and without 
p53 gene mutation. 
4.3c Concordance between IHC and S S C P / C S G E 
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Twenty nine samples had been examined for both p53 protein expression and 
p53 mutation. Sixteen cases were either positive in both tests or negative in both 
tests. The concordance rate between the two methods w a s 5 5 % . 
Concordance between p53 S S C P / C S G E and p53 IHC 
S S C P / C S G E 







4.4 MDR1 gene expression 
4.4a MDR1 gene expression in normal tissue and tumors 
Only 25 of the 31 cases had sufficient tissue available for MDR1 gene expression 
analysis. These include 15 intestinal, eight diffuse, and two mixed type tumors. 
Fourteen of them (56%) were positive for MDR1 gene expression. Eleven out of 
the fifteen of the intestinal type gastric tumors were positive for MDR1 gene 
expression. Both of the two mixed type cases showed MDR1 gene expression, 
however, only one out of the eight cases with diffuse type showed MDR1 gene 
"expression. Compared with the diffuse type, the intestinal type gastric carcinoma 
w a s significantly {Fisher's exact test p= 0.009) associated with MDR1 gene 
expression. However, there is no statistical significant correlation between the 
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MDR1 gene expression and other clinical parameters. S u m m a r y is shown in 
Appendix 12. 
Six cases have detectable MDR1 gene expression in the normal tissue; the 
remaining cases have no MDR1 gene expression in the normal tissue. Five of 
them have MDR1 overexpression in their respective tumors; the remaining one 
has lower MDR1 expression in tumor than the normal. Representative P G R 
products are shown in Figure 7. 
A table summarizing the p53 and MDR1 gene expression results is shown in 
Appendix 13. 
4.4b Correlation of MDR1 expression and chemosensitivity 
There w a s no significant difference between tumors which are M D R 1 positive 
and those which are MDR1 negative for any of the drugs. 
M e a n (standard deviation)  
of ICso and M D R 1 expression  
M D R +ve M D R -ve 
5-fluorouracil archival 173.80 (175.54) 78.87 (73.18) 
5-fluorouradl fresh 0.063 (0.043) 0.041 (0.019) 
L o g IC50 L o g IC50 
、 Adriamycin 2.75 (1.56) 2.48 (1.59) 
Cisplatin 3.02 (1.48) 2.90 (0.81) 
Daunorubicin 3.20 (1.07) 3.67 (0.82) 
Epirubicin 3.65 (1.06) 3.34 (1.30) 
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4.5 Pseudobiopsies 
The chemosensitivity assay results of the 6 pseudobiopsies did not correlate well 
with their parent tumors. The intra-assay results of the four replicates for each 
pseudobiopsy or tumor samples were very similar. 
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5. DISCUSSION 
5.1 p53 analysis of the tumors 
5.1a Immunohistochemistry versus mutational analysis 
T h e methods for demonstrating p53 alterations can be essentially grouped into 
three fundamental techniques: a) immunohistochemical detection (IHC) of 
p53 protein accumulation; b) D N A sequencing; and c) mobility shifts of 
polymerase chain reaction-generated D N A fragments. In this study, two 
methods, IHC and detection of mobility shifts by S S C P and C S G E to screen for 
p53 mutation, were used. 
T h e immunohistochemical technique is technically simple, economical and can 
be applied to formalin-fixed paraffin-embedded archival tissues (Kerns et al. 
1992; Moyret et al. 1994). It allows the signals to be localized to tumor cells 
with preservation of morphological details and is cheaper and less labor 
intensive than molecular approaches such as R T - P C R or western blot (Yandell 
and Thpr 1993). However, studies have s h o w n s o m e mutations cannot be 
detected by IHC (Hamelin et al. 1994; Louis et al. 1993). Moreover the 
detectable expression of p53 can occur in the absence of gene mutations 
(Baas 10 et al. 1994). It has been pointed out that posttranslational 
mechanisms can stabilize wild-type p53 as a result of mdm-2 oncogene 
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product ( M o m a n d et al. 1992). A s a result, expression of normal p53 can be 
detected and this had been reported in gastric tumors without p53 mutation 
(Poremba etal. 1995). 
Immunohistochemical technique also has another limitation. That is, 
p53-negative staining does not conclude the presence of normal p53 gene 
because most mutations caused loss of both alleles or in truncated forms of 
p53 with no abnormal protein produced (Eicheler et al. 2002; P o r e m b a et al. 
1995). T h e truncated forms of p53 protein can be the result of splicing 
mutations, nonsense mutations, exon skipping and intronic point mutation. 
False-positive and false negative result m a y occur depending on the antibody 
specificity and on the location of the mutation. In fact, using different 
antibodies to detect p53 expression, Eicheler et al. reported 2 5 % to 4 0 % false 
negative result (Eicheler et al. 2002). Previous studies also suggested that 
approximately 2 0 % or more of the tumors with mutant p53 had false negative 
results by exclusive immunohistochemical studies (Kappes et al. 1995). In 
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addition，studies have s h o w n s o m e mutations can be detected by 旧 C but not 
S S C P or C S G E or vice versa (Hamelin et al. 1994; Louis et al. 1993). While 
s o m e believed that IHC analysis m a y be more sensitive than molecular 
analysis (Umekita et al. 1994), others found the opposite might be true (Ueno 
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et al. 2000). It s e e m s that the combination of the two methods will enhance 
the detection sensitivity. 
In this study, the monoclonal antibody D O - 7 w a s selected for two reasons. 
Firstly, it has been shown to be one of the most sensitive antibodies for the 
detection of p53 expression in paraffin-embedded section (Baas et al 1994; 
C a m p a n i et al. 1993). Secondly, D O - 7 has been reported to give less 
background compared with other p53 protein antibodies ( M c M a n u s et al. 
1994). 
D O - 7 recognizes an epitope of h u m a n p53 protein located in the N-terminal 
part of the molecule, between amino acids 19 and 26 (Baas et al. 1994). 
D O - 7 is positive for wild-type p53 as well as for mutant-type p53; however, the 
half-life of the wild-type p53 protein is as short as 10 min (Baas et al. 1994; 
Umekita et al.1994) as compared to several hours half life duration of mutant 
form of p53 (Hinds et al 1990). In addition, mutated p53 protein accumulates 
in the nucleus as、a consequence of its binding to other oncogenic proteins, 
which prolongs its half-life (Finaly et al. 1998). Therefore, it is c o m m o n l y 
believed that most positive cells represent mutant p53. Molecular studies 
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have confirmed point mutations in the gene to be the most usual cause of p53 
accumulation detectable by immunohistochemistry (Bartek et al. 1991; Tamura 
etal. 1991). 
5.1 b Methods of mutational analysis 
Various molecular methods are available to detect p53 mutation, for instance, 
D N A sequencing. Although D N A sequencing can correctly identify the type 
and location of mutation, it requires a ratio of wild-type/mutant alleles of 3/1 or 
less (Cheng et al. 1992). Furthermore, sequencing is expensive and labor 
intensive; thus, it is less than optimal for investigating large series of patients 
(Moyret et al.1994; Nigro et al.1989). 
T h e two techniques used in this study, S S C P and C S G E , are the two most 
frequently used techniques to prescreen the presence of mutation to identify 
samples that are likely to harbor mutation. They are rather simple and not 
labor intensive. Denaturing gradient gel electrophoresis ( D G G E ) , and 
,temperature gradient gel electrophoresis ( T G G E ) are two other alternative 
methods available for prescreening mutation; however, they are expensive and 
difficult to set up than S S C P than C S G E . 
T h e principle of S S C P is based on the fact that single-stranded D N A molecules 
take on specific sequence-based secondary structures (conformers) under 
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nondenaturing conditions. Molecules differing by as little as a single base 
substitution m a y form different conformers and migrate differently in a 
nondenaturing polyacrylamide gel (Sheffield et al. 1993). T h e aberrant 
migration pattern suggests the presence of mutation or polymorphism. 
Factors, such as the length of the P G R product, the position of the mutation, 
the nature of the mutation (i.e., transition versus transversion), and the 
sequence composition of the D N A fragment, play a role in the sensitivity of 
S S C P . In addition, the electrophoresis conditions also influence the 
electrophoretic mobility of the D N A molecules (O'Connell et al. 1999). 
T h e optimal conditions for S S C P have been suggested. First, the size 
fragment for sensitive detection should around 150bp to 250bp in length 
(Sheffield et al. 1991). Within this range, Sheffield et al. reported that the 
sensitivity of S S C P ranged from 7 2 % to 9 7 % (Sheffield et al. 1991 )• There is 
an upper and lower limit of size for sensitivity of this method (Sheffield et 
al.1991). In addition, addition of 10-15% sucrose or glycerol improves 
mutation detection (Glavac and D e a n 1993). Lastly, use more than one set of 
gel conditions to increase the likelihood of detecting mutation. 
It w a s reported S S C P detected mutation in samples contained as little as 1.5% 
mutant D N A (Dix 1994) and has an estimated sensitivity range from 6 0 % to 
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9 0 - 1 0 0 % in detecting point mutation (Hayashi 1991，1993). 
T h e S S C P conditions were optimized in this study. T h e P G R fragments were 
within the suggested range. T w o types of gels, M D E and 6 % polyacrylamide 
nondenaturing gels, were used to improve the sensitivity of detection. In 
addition, glycerol w a s added to the nondenaturing gel. 
Similar to the S S C P , C S G E prescreens mutation or polymorphism by detecting 
aberrant electrophoretic migration. C o m p a r e d to the S S C P , this method 
requires little standardization, has a greater capacity (more samples can be 
run on one gel) and most importantly, it is a non-radioactive technique. 
D N A heteroduplexes are formed by one strand of wild-type and one strand of 
mutated D N A . In the presence of two alleles, in which there is a mutation in 
one alleles, D N A fragments after amplification could form heteroduplexes 
(wild-type and mutated) and homoduplexes (both wild-type or both mutated). 
This p h e n o m e n o n would cause migration shift pattern in C S G E gel. In fact, 
C S G E is intended to separate the heteroduplexes and homoduplexes in a 
non-proprietary acrylamide gel matrix (Ganguly et al. 1993). T h e optimal 
length of the P G R fragments is between 250-500bp (Ganguly 2002). In 
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addition, mildly denaturing solvents, ethylene glycol and formamide, can 
amplify the tendency of mismatches to produce subtle conformational change 
such as bends in the double helix and thereby increase the differential 
migration of D N A heteroduplexes and homoduplexes during gel 
electrophoresis (Ganguly 2002). 
There are very few studies that compare the sensitivity of S S C P and C S G E . 
However, one study had suggested that the sensitivity of C S G E is superior to 
that of S S C P in detecting mutation of BRCA1 gene. However, as genes differ 
in structures, comparison cannot be m a d e because the electrophoretic mobility 
of D N A is dependent on the conformation, which is sequence-dependent 
( M c m a n u s et al. 1994). N o study has compared the two methods in detecting 
p53 mutation. 
In m y study, the primers for prescreening p53 mutation covered intron 3 to 
intron 9. Most "hot spots" of p53 mutation are found within this region 
(Hollstein et al. 1991). 
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Since neither S S C P nor C S G E can confirm the presence of mutation, it is not 
known if the tumor samples really had mutation or polymorphism, or neither. 
In addition, the methods give no information regarding the nature of the 
mutation and any functional consequence due to mutation. 
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5.1c Comparing IHC results with previous findings 
In this study, immunohistochemical analysis revealed 20 cases (65%) of the 
gastric tumor samples had p53 accumulation. Only the nuclear staining of 
p53 positive w a s considered immunopositive，and faint cytoplasmic staining 
without nuclear staining w a s considered negative. This is because in most 
cases of cytoplasmic localization of p53 represents wild-type p53 (Bosari et al. 
1995; Inoue et al. 1994; Moll et al 1992). 
There were a heterogeneous distribution pattern of p53 positive cells in the 
tumors, showing areas with a high n u m b e r of p53 positive tumor cells 
neighboring areas with only a few p53 positive tumor cells. This intratumoral 
variability in p53 expression has also been described in s o m e reports (Gabbert 
et al. 1995; Victorzon et al. 1996). This is w h y grading system w a s used. 
Other studies s h o w e d 2 0 - 7 0 % of the gastric cancers overexpressed p53 
protein (Boku et al. 1998; Craanen et al. 1995; H o n g et al. 1994; Lee et al. 
1998; Urn et al. 1996; Victorzon et al. 1996). T h e difference in the data could 
due to the different paraffin block treatments and staining procedures, scoring 
criteria, subjective interpretation of the investigators, and the histologic types of 
gastric tumor samples (intestinal and diffuse types). Therefore, it is difficult to 
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m a k e a direct comparison between the results obtained by different groups. 
In addition, Lee et al. reported that p53 expression tends to be associated with 
advanced rather than early and intestinal than diffuse cancer (Lee et al. 1998). 
M y study revealed all stage 4 gastric cancers had p53 accumulation with no 
statistical significant difference between early (Stages I and II) and advanced 
(Stages III and IV) tumors nor between intestinal type (55%) and diffuse type 
(55%) gastric cancers. 
5.1d Comparing S S C P / C S G E results with previous findings 
In this study, 5 2 % of the tumor samples showed mobility shifts. A similar 
. f r e q u e n c y has been reported in other studies of gastric cancer ( 5 0 % - 6 5 % ) by 
using S S C P (Kim et al. 1991; Hongyo et al. 1995; Imazeki et al. 1992). S o m e 
other studies have reported lower frequencies (33-38%) (Poremba et al.1995; 
Tamura et al. 1991; Uchino et al. 1993). T h e varying frequencies could reflect 
differences in the types of tissue samples (frozen and embedded-paraffin 
block), processing of tumor tissue sample for D N A extraction, or it m a y reflect 
differences in mutation detection technique. 
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This study have found 11/29 (38%) of gastric carcinomas with mobility shift at 
exon 4，for exon 5 and exon 6, each had 3 % (1/29) of gastric tumors with 
mobility shift, 1 7 % (5/29) of gastric tumors found to have band shift at exon 8/9 
and none w a s found in exon 7 by either S S C P or C S G E . 
Mutation outside the conserved regions is believed to be rare. Thus, very few 
reports have s h o w n studied exon 4 of p53 gene. However, in this study, 3 8 % 
of the samples s h o w e d mobility shift by C S G E . A s direct sequencing has not 
yet been done, it is uncertain whether the shifts are truly due to mutations since 
mobility shift m a y represent gene polymorphism. In fact, a study on gastric 
cancers from 26 British patients identified two silent mutations in exon 4 (Sud 
et al. 2001). Other types of mutations, including nonsense and frameshift 
mutations, in exon 4 of p53 gene were also found in gastric cancers (Shepherd 
et al. 2000). T h e gastric cancer cell line SK-GT-4 is k n o w n to have 17 bp 
deletion in exon 4 (Altorki et al. 1993). Therefore, mutation in exon 4 is 
expected to be found in gastric cancer. T w o polymorphism sites have been 
reported within this region. O n e site, located at codon 72， is frequently 
associated with polymorphism in gastric cancers (Shepherd et al. 2000). T h e 
genotypes frequently were 5 4 % for arg/arg, 3 3 % for arg/pro and 1 4 % for 
79 
pro/pro (Shepherd et al. 2000). T h e other site of polymorphism is located in 
codon 36. 
Most studies were on exons 5-8，with the reported range of detectable 
mutations between 3 8 % and 6 7 % for gastric cancers (Flejou et al. 1999; 
Gleeson et al. 1998; Shiao et al. 1994; Yokozaki et al. 1992). In this study, 
only 7 of the 30 cases (23%) s h o w e d mutations in exons 5 to 8/9. This is 
relatively low compared with the published figures. 
Nevertheless, compared with other studies that had completed the direct 
sequencing after prescreened mutation by S S C P , the results of this study are 
similar. For example, exon 5 mutations were found in 3 % of the tumor 
samples in this study, compared with 8 % and 4 % reported by Ishida et al. and 
H o n g et al. (Hong et al. 1994; Ishida et al. 1997). However, two other studies 
reported mutation rates of over 1 0 % (Flejou et al. 1999; Uchino et al. 1993). 
T h e 3 % figure .for exon 6 w a s similar to the figures published which range from 
0 to 5 % (Dix et al. 1994; Hsieh et al. 1996). 
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T h e result for exon 7 (0%) is the least expected. T h e published figures ranged 
from 6 % to over 1 0 % (Ishida et al. 1997; Ochiai et al. 1996; P o r e m b a 1995; 
Uchino et al. 1993). 
T h e 1 7 % of the tumors showing aberrant mobility m o v e m e n t in C S G E for exon 
8/9 is higher than s o m e studies showing about 1 0 % (Flejou et al. 1999; Ishida 
et al. 1997; Uchino et al. 1993). However, Gleeso etal. reported 2 1 % of their 
gastric tumor with band shifts by S S C P and confirmed mutation in this region 
(Gleeso et al. 1998). T h e region studied by most other groups w a s smaller 
than mine. T h e primers for exon 8/9 cover intron 7 to intron 9. C o m p a r e d 
with other groups, m y primers examined additional approximately 300 bp that 
w a s not done by other groups. Thus, it is possible that mutation or 
polymorphism lies within this region. In fact, one study s h o w s a gastric cancer 
cell line harbors mutation in the intron 7 (Kim et al. 1991). 
5.1e Correlation of IHC and S S C P / C S G E results 
There is 55%、concordance between IHC and S S C P / C S G E . There has not 
been a study done to investigate the concordance between IHC and C S G E on 
p53. Therefore, no comparison can be m a d e . However, studies on p53 
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protein accumulation and S S C P have demonstrated similar findings. For 
example, 5 1 % (Scarpa et al 1993)，57% (Louis et al. 1993)，69% (Dix et al. 
1994) and 7 3 % (Lim et al. 1996; S o o n g et al. 1996) concordance rates were 
reported between IHC staining and S S C P . Others have found lower 
concordance (Pezeshki et al. 2001). 
Assuming the mutations detected by S S C P / C S G E indeed harbored mutations, 
there are four "false negative" cases, i.e. those tumors presumably with gene 
mutations but without immunohistochemical abnormalities. O n e explanation 
is that the tumors harbor frameshift mutation in p 5 3 gene, resulting in 
premature stop codons or early termination of transcription. While readily 
detectable by S S C P or C S G E , such frameshift produced truncated or 
antigenically altered proteins that were not noted with D O - 7 . For instance, 
truncation in the carboxyl terminal of p53 protein can alter the ability of p53 to 
form oligomeric complexes that are necessary for protein stability (Milner et al. 
1991). Antigenically altered proteins m a y not bind to other cellular proteins, 
such as heat shock protein 70，that prolong half-life (Finaly et al. 1998). S u c h 
unstable complexes or unbound p53 would therefore not be detected by D O - 7 . 
In addition, Bennet et al. have suggested two other m e c h a n i s m s that m a y 
account for p53 gene abnormalities without p53 protein accumulation: 
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deletion of both p53 alleles and rapid degradation of the mutant p53 protein. 
In these cases, deletion of both p53 alleles did not happen because all cases 
had P G R amplified product. However, whether deletion of one of the two 
alleles had occurred has to be further analyzed by molecular techniques such 
as fluorescence in situ hybridization (FISH). 
Furthermore, Shepherd et al. have shown that most gastric cancer harboring 
p53 mutation in exon 4 are immunonegative (Shepherd et al. 2000). 
Certain proteins, such as the h u m a n papillomavirus ( H P V ) E 6 oncoprotein, are 
known to promote the proteolysis of p53 protein (Scheffner et al 1990) and 
m a y account for the low levels of p53 in cervical carcinomas (Scheffner et al 
1990; Werness et al. 1990). However, up to now, there is no evidence of H P V 
involvement in gastric cancer. Thus, the latter two hypotheses are unlikely to 
be explanations for the lack of protein accumulation in m y cases. 
Furthermore, polymorphisms m a y lead to migration shifts on S S C P with 
normal protein products. Indeed, Louis et al. had s h o w e d that polymorphism 
in codon 213 led to migration shift detectable by S S C P but not accompanied 
by immunohistochmically detectable p53 (Louis et al. 1993). 
O n e last explanation for false negative is that antigenic determinant of the p53 
protein m a y be lost during fixation and embedding. 
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Nine cases of the 29 cases were "false positive", that is, they are 
immunohistochemically detectable p53 protein but harbor no identified genetic 
changes in exon 4 through 9. There are severeal possible explanations. 
These tumors m a y have mutations outside of the studied regions of the gene. 
T h e mutations perhaps locate in the promoter region, or other intronic or 
exonic regions, resulting proteins with long half-life. Another explanation is that 
the normal p53 is overexpressed or has prolonged half-life by mechanisms 
independent of the gene mutation. Thus, DO-7, that recognizes both normal 
and mutated proteins, could detect the presence of the protein. This 
observation is supported by a study showing detectable protein accumulation 
without p53 gene mutation in exons 2-11 (Lehman et al. 1991). 
T h e sensitivity of S S C P / C S G E or/and immunohistochemical techniques m a y 
be very different. Microwave antigen retrieval technique could increase the 
risk of producing false positive results (Urn et al. 1996). However, the 
frequency of this occurrence is not known. T h e conditions in S S C P / C S G E 
have been optimized. T h e sensitivity of S S C P / C S G E in this study can only 
be determined after direct sequencing of all the studied exons for all the cases 
is done. 
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5.2 MDR1 expression 
5.2a Methods for detecting MDR1 expression 
A n u m b e r of methods can be used to detect P-glycoprotein at R N A and protein 
levels. Techniques such as flow cytometry, immunohistochemistry, and 
western blotting analysis are frequently used to look at the protein expression 
(Beck et al.1996; Hotta et al. 1999). Each of these methods has its limitation. 
For example, the reactivity of immunohistochemistry (IHC) is dependent on the 
sensitivity and specificity of the antibody, antigen retrieve process, and other 
technical pitfalls of IHC. Use of a combination of antibodies directed at 
different epitopes of the P-glycoprotein molecule is necessary, as reactivity 
with a single anti-P-glycoprotein antibody cannot be taken as proof of actual 
presence of P-glycoprotein (van der Valk et al. 1990). T h e commercially 
available antibodies used to detect P-gp expression recognize different 
epitopes (Beck et al. 1996), and s o m e are known to cross react with other 
glycoproteins (van der Valk et al. 1990). 
Northern blot analysis, slot blot analysis, RT-polymerase chain reaction, and in 
situ hybridization (ISH) are used to detect the expression of M D R 1 R N A 
(Herzog et al. 1992; Savarai et al. 1997). A m o n g these methods, only in situ 
hybridization can examine R N A expression in individual cells. However, this 
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method is labor intensive and time consuming. Although northern blot and 
slot blot are relatively sensitive, they are subjected to non-specific binding that 
interferes with the results (Gerlach et al. 1986; Ramachandran and Melnick 
1999). Yet, these methods d e m a n d at least 0.1-1.0pg of the specific m R N A , 
which equals to 10^-10® molecules to obtain result (Bradley et al. 1989). This 
d e m a n d of large quantity of m R N A is a limiting factor in clinical practice. 
Moreover, in situ hybridization, together with northern blot analysis and slot 
blot analysis is not sensitive enough to detect samples with low levels of M D R 1 
expression (Gerlach et al. 1986). Gerlach et al. suggested only P G R is 
sensitive enough (Gerlach et al. 1986). Indeed, P G R is quick, efficient, and 
specific. However, this assay is unable to determine the heterogeneity of 
m R N A expression in a tissue specimen, which is a potential problem of this 
method. T h e assay only provides an overall m e a n m R N A level for the whole 
sample analyzed. Thus, it cannot discriminate between m a n y cells with 
similar MDR1 m R N A levels or a few cells with very high levels of gene 
expression, whereas IHC and ISH can reveal the heterogeneous pattern of the 
M D R 1 protein expression. 
T h e rationale for the conditions used in the R T - P C R of this study has been 
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explained in the introduction. D u e to the technical limitation, the band 
intensity or signal of P G R fragment could not be quantified by laser 
densitometry. T h e result of the MDR1 expression w a s based on assessment 
and comparison of the P G R product intensity. A s the result is strictly 
qualitative, increase in MDR1 expression in the tumors compared with their 
normal counterpart w a s classified as positive or negative, with no attempt to 
grade the levels of expression. 
Expression of ^-microglobulin gene served as an endogenous control in this 
study, and it w a s shown to be expressed at relatively constant levels w h e n 
consistent R N A loading could be documented by gel electrophoresis and 
ethidium bromide staining (Kang et al. 1995; Murphy et al. 1990). Although 
j3-actin is an alternative, ^-microglobulin has been c o m m o n l y used as an 
internal reference for the determination of MDR1 transcript levels in 
P C R - b a s e d studies (Clifford et al. 1994; Kuwazuru et al. 1990; N o o n a n et al. 
1990). Amplification of the m R N A revealed ^-microglobulin expression in all 
the tumor samples, confirming the satisfactory quality of the R N A . 
Moreover, MDR1 specific c D N A sequences were amplified using a pair of 
primers derived from different exons (exon 21 and exon 22) of the MDR1 gene, 
separated by a long intron (Chen et al. 1990)，to prevent amplification of 
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genomic D N A sequences that might contaminate cellular R N A preparations. 
A s the amplified MDR1 c D N A is only 167bp long，even significantly degraded 
R N A could be used as template. Moreover, this pair of primers w a s selected 
because they would not amplify the closely related MDR2 c D N A sequence 
(Noonan et al. 1990). 
5.2b Comparing MDR1 expression results with published data 
M y study found 5 6 % of the tumors to be MDR1 positive. T h e MDR1 expression 
w a s thus an intrinsic property of the tumors and not induced. 
Gurel et al. has found M D R 1 expression in 8 7 % of patients (Gurel et al. 1999). 
In contrast, Ikeda et al. found no MDR1 gene expression in the gastric cancer 
‘ cell lines (Ikeda et al. 1998). However, 25 cycles of R T - P C R were performed 
in Ikeda's study, and this might not be sufficient to detect low level of 
expression. T h e y also did not find MDR1 expression in lung cancer cell lines. 
Fan et al. reported that only 1 0 % of the gastric cancers s h o w e d 
overexpression of MDR1 gene (Fan et al. 2000). However, their criteria for 
determining positive result are different from those in this. 
B y other methods, such as dot- blot technique, Vol I rath et al. reported MDR1 
detection in 9 of the 10 non-tumor gastric samples and 8 of the 10 gastric 
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tumor samples (Vollrath et al. 1991). By slot blot analysis, Wallner et al. 
revealed over 4 0 % of gastric tissue possessed MDR1 expression (Wallner et 
al. 1993). M o s c o w et al. also detected positive MDR1 expression in gastric 
cancer (Moscow et al. 1989). But, Goldstein et al. concluded relatively low 
expression in gastric tumors in contrast to other types of tumors (Goldstein et 
al. 1989). 
Furthermore, by immunohistochemical analysis, various M D R 1 expression 
rates were reported. While two studies showing appromiately 8 0 % of gastric 
cancer patients had expression for M D R 1 (Gurel et al. 1999; Lacueva et al. 
2000) and another one found 5 4 % positive rate (Furukawa et al 1998), M D R 1 
expression w a s reported in 3 6 % of the gastric tissue samples in one study 
(Orita et al 1994). Yet, 3 3 % of gastric samples s h o w e d positive result by flow 
cytometry (Fuji et al. 1995). T h e discrepancy m a y due to the sensitivity of the 
assays, the patient selection, and the analysis criteria. In fact, W a n g et al. 
s h o w e d that while MDR1 gene expression is detected in 8 4 % of the samples 
by R T - P C R , only 2 5 % of the samples has expression by 
immunohistochemistry, suggesting that the R T - P C R is more sensitivity than 
IHC ( W a n g et al. 1997). However, it m a y be possible that the m R N A is not 
always translated to protein, thus, IHC gives a lower detection rate. 
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There were five of out the 25 cases showing MDR1 expression in the normal. 
T h e remaining cases have no detectable MDR1 expression in the normal. 
These five cases have an elevated level of MDR1 m R N A expression in the 
tumor. This suggests that MDR1 gene is already expressed in the normal 
cells, and then it continuous to increase w h e n normal cells convert into 
malignant cells. However, in most of the time, MDR1 gene expression s e e m s 
to be downregulated to an undetectable level in normal tissue. This is in 
consistent with the finding that M D R 1 is only partly expressed in the normal 
tissue of the stomach (van der Valk et al. 1990). There s e e m s to exist 
m e c h a n i s m s that upregulate the MDR1 expression in the tumors. Indeed， 
p53 gene mutation has s h o w n to upregulate the MDR1 gene expression (Chin 
et al. 1992; N g u y e n et al. 1994). However, only 4/14 cases have both MDR1 
overexpression and p53 mutation detected by S S C P / C S G E in the tumor and 
9/14 cases have both MDR1 overexpression and p53 accumulation. O n e 
explanation is that p53 gene mutation m a y be only one factor that determines 
MDR1 gene expression. Another explanation is that the gene regulation of 
MDR1 is dependent on the mutational location of p53. Strauss and H a a s 
illustrate only specific mutant p53 is capable of activating the MDR1 gene 
promoter (Strauss and H a a s 1995). 
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There w a s one case in which higher MDR1 expression w a s found in the 
normal than the tumor. Several repeated R T - P C R and m R N A re-extraction 
had been performed to confirm the s a m e phenomenon; therefore, technical 
error is unlikely accounted for this observation. Perhaps, the normal gastric 
tissue intrinsically overexpressed the gene. Increased levels of MDR1 are 
most often due to increased gene expression (not gene amplification) in 
h u m a n (Cole 1992; Stow and Warr 1991). In fact, it has been suggested that 
the hypomethylation status of C p G sites at the promoter region is associated 
with the overexpression of the h u m a n MDR1 gene (Nakayama et al. 1998). 
In this case, the tumor might harbor genetic alteration that led to 
downregulation of the MDR1 gene expression. 
Another p h e n o m e n o n found in this study is the association of MDR1 
expression with intestinal type gastric tumors. A s in the Japanese 
classification, most of the well differentiated gastric cancers correspond to the 
intestinal type tumors, similar association w a s observed for the well 
differentiated tumors (Fujii et al. 1995; Mizoguchi et al. 1990; Park et al. 1990). 
This suggests MDR1 expression m a y be associated with more differentiated 
histological type of cancer. 
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Concerning the likelihood of false positive due to contamination with 
inflammatory cells, Kang et al. found that contamination of the tumor sample 
with 丁 lymphocytes and monocytes does not significantly increase the level of 
MDR1 expression (Kang et al. 1995). 
5.2c Correlation between chemosensitivity and MDR1 gene expression 
There are very few papers published on gastric tumor to demonstrate 
correlation between chemosensitivity and MDR1 expression. In one study 
where the investigators compared gastric cancer cell lines to that of the 
colorectal cancer, they found gastric cancer cell lines expressed lower level of 
MDR1 were relatively sensitivity to cisplatin, adriamycin and mitomycin (Park 
et al. 1990). In contrast, colon cancer cell lines expressed high level of MDR1 
were relatively resistant to antitumor drugs (Park et al. 1990). In another 
study on gastric cancer, the expression of M D R 1 is significant correlated with 
response to adriamycin treatment (Orita el al. 1994). However, it is not 
correlated with cisplatin treatment (Orita el al. 1994). Moreover, Lai et al. 
reported no apparent correlation between cell line expression of MDR1 and the 
sensitivity of the lines to five drugs, including doxorubicin, etoposide, and 
cisplatin (Lai et al. 1989). 
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In this study correlation w a s found between chemosensitivity to cisplatin 
treatment and MDR1 expression. There appears to be mechanisms other 
than MDR1 that determine the chemosensitivity. For instance, reduced 
accumulation, detoxification due to increased glutathione, and enhanced D N A 
repair m a y explain the resistance in cisplatin treatment. T h e resistance to 
5-Fu is not considered to be due to the effect of P-glycoprotein (Eastman 1991 ； 
Peters and van Groeningen 1991). At least two other mechanisms have been 
suggested for multidrug resistance: the non-P-glycoprotein mediated 
mechanism and atypical M D R mechanism. Atypical M D R is believed due to 
an alteration in the level or sensitivity of topoisomerase 11. And, 
non-P-glycoprotein mediated mechanism w a s first s h o w n to confer drug 
resistance in h u m a n lung cancer cell lines (Baas et al. 1990). T h e protein, 
M R P (multidrug resistance-associated protein) w a s later identified (Cole et al. 
1992).. 
Maehara et al. found the sensitivity rate of poorly differentiated tumors to be 
higher than the well differentiated tumors against all six drugs, included 3 
drugs used in the present study (Maehara et al. 1987). This suggests that 
poorly differentiated tumors probably respond to chemotherapy better than 
well differentiate ones. Similar findings were also observed in gastric cancers 
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(Fuji et al. 1995; Park et al. 1990). Are the well differentiated tumors more 
chemoresistant because of MDR1 overexpression? T h e present study found 
no correlation between the chemosensitivity in vitro and MDR1 expression. 
MDR1 is not a predictor for the chemosensitivity, and no assay has 
demonstrated a direct correlation so far. 
Even though it has been suggested that M D R 1 expression m a y be induced by 
chemotherapy in gastric cancer patients (Chung et al. 1996), the tumors in this 
study were collected before the patients received any chemotherapy. T h e 
MDR1 expression w a s thus an intrinsic property of the tumors and not induced. 
5.3 Chemosensitivity testing 
5.3a Chemosensitivity testing method 
There is no standard chemotherapy for gastric cancer (Ajani 2000) because it 
is well k n o w n that individual response to chemotherapy differs. T h e overall 
efficacy of chemotherapy in gastric cancer is rather low，in the range of 5 - 3 0 % 
for single agent depending on the drugs (De Vivo et al. 2000). Moreover, 
声. 
about one-third of these patients develop side effects. Gastric cancer is more 
resistant to anticancer drugs than other cancers, for example, esophageal 
carcinoma (Kelsen and Atiq 1991), and small cell lung cancer (Mitsuhashi et al. 
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1992). Thus, in vitro determination of the drug sensitivity and resistance 
before chemotherapy could exclude drugs that are ineffective and toxic to 
patients. 
T h e pattern of chemosensitivity for each drug in different parts of the world 
m a y vary. T h e etiology and the distribution of patients' age, tumor location， 
histological types and other clinical data are not uniform throughout the world. 
T h e drug sensitivity response of patients cannot be predicted by the results 
from studies of a different region. For these reasons, a standardized 
chemosensitivity testing method has to be established. At present, the types 
and protocols of assays are not always comparable, for instance, the drug 
concentration and the incubation time. 
T h e value of chemosensitivity testing has been challenged. However, it has 
been s h o w n that in a study the overall and disease-free survival rate of the 
gastric cancer patients treated with drugs that are sensitive in the assay is 
significant higher than the patients treated with drugs that are resistant (Kubota 
1997). 丁his、implies chemosensitivity testing is useful, and it m a y aid the 
clinicians in drug selection for patients as a clinical routine. 
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T h e chemosensitivtiy test in this study utilizes a tetrazolium compound, 
[3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), and an 
electron coupling reagent, phenazine ethosulfate ( P M S ) to determine the 
sensitivity of the anti-neoplastics drugs. In fact, this type of assay has been 
used widely in Japan (Do et al. 2000). T h e c o m p o u n d is a modification of the 
M T T (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) which has 
often been used in chemosensitivity research (Saikawa et al. 1994; Y a m a u e et 
al. 1991). T h e M T T assay is reproducible, and the evaluation rate of this 
assay is high (Bellamy 1992). Furthermore, it has been shown to be 
comparable to other chemosensitivity assays (Keepers et al. 1991; Pieters et 
al. 1989; Rubinstein et al. 1990; T w e n t y m a n et al. 1989) and the predictive rate 
for drug response in patients w a s found to be high (Shimoyama et al. 1989). 
Most importantly, the M T T and M T S assays require fewer cells than other 
assays, such as clonogenic assays. 
T h e theory behind the M T S is similar to that of the M T T and work in a similar 
manner. T h e soluble form of M T S is reduced by the mitochondria of viable 
cells to form an intensely colored, formazan product (Cory et al. 1991). It 
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measures the activity of the succinic dehydrogenase e n z y m e in the 
mitochondrial. T h e formazan product formed by M T S c o m p o u n d is soluble. 
T h e amount of formazan product, registered as the absorbance reading by the 
spectrophotometer, is proportional to the n u m b e r of viable cells. However, 
comparing to the M T T , M T S is simpler and it eliminates experimental error and 
data misinterpretation associated with the technical difficulties. For example, 
in M T T assay, the culture m e d i u m must be removed (by aspiration) at the end 
of the culture period. This step could cause variable n u m b e r of cells to be 
taken out from the wells and lead to underestimate or overestimate the drug 
effectiveness. Moreover, only the soluble M T S is required to be added in the 
M T S method, in contrast to the two steps procedures in the M T T assay, in 
which the solubilization solution ( D M S O ) and the insoluble M T T have to be 
added. This additional step can lead to experimental error. 
Depending on the assay method, drug exposure conditions including drug 
concentration, exposure time, and culture duration affect the results of the in 
vitro chemosensitivity test (Mitsuhashi et al. 1992). There are m a n y 
intra-experimental variations and conditions. In this study, three days drug 
exposure followed by one day incubation w a s chosen as the duration of the 
test. T h e conditions chosen were based on the previous studies and initial 
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experiment. Cells are required to be cultured for sufficient time to allow for 
the effect of cell death and loss of mitochondrial activity to be seen by the M T T 
agent (Mitsuhashi et al. 1992). Continuous exposure is required to minimize 
the frequency of "false negative" result (Park et al. 1987). Other conditions 
such as shorter drug exposure period and incubation time had been tested, 
and the result suggested the short incubation time w a s not enough to induce 
cell death and determine the IC50. T h e initial experiment in this study 
indicated continuous drug exposure for three days w a s appropriate for 
determining the IC50. However, longer incubation time resulted in the death 
of control cells because they had gone into plateau phase. A s a result, the 
O D reading might have overestimated the antitumor activity. Indeed，different 
conditions, for examples, two days, three days, and four days drug exposure, 
had been also used by the researchers to assess chemosensitivity for gastric 
cancer (Saikawa et al. 1994; Y a m a u e et al. 1992; Y a m a u c h i et al. 1991). 
Three days exposure w a s in the range of preferred conditions, has been 
suggested to be optimal (Carmichael et al. 1987). Moreover, 5-fluorouracil is 
, 
k n o w n to be time-dependent antitumor drug (Isobe et al. 1987); thus, its 
antitumor activity is dependent on the incubation time, and three days of 
incubation period had been suggested for the assessment of its activity (Suto 
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et al. 1989). Moreover, it is k n o w n that the antitumor drug cisplatin is entirely 
inactivated after 48 hours in the culture m e d i u m and only 1 7 % of the drug is 
retained after 24 hours in the culture m e d i u m (Yamauchi et al. 1991). 
Therefore, addition of n e w fraction of drugs each day w a s done to ensure drug 
effectiveness is accurately determined. 
Six serial dilutions were used for each drug test. T h e y had covered the 
concentrations used in the previous studies to examine gastric cancer 
chemosensitivity by the M T T assay (Kimura et al. 1992; Saikawa et al. 1994; 
Suto et al. 1989; Y a m a u e et al. 1992，1991). In comparison, previous studies 
usually used one threshold concentration to determine sensitivity (Kimura et al. 
1992; Saikawa et al. 1994; Suto et al. 1989; Y a m a u e et al. 1992, 1991), and 
inhibition rate of m o r e than 5 0 % cell viability w a s considered to be sensitive 
(Suto et al. 1989; Y a m a u e et al. 1992，1991). 
In addition, determination of optimal drug concentration for the evaluation of 
chemosensitivity is problematic ( Y a m a u e et al. 1992). T h e area under the 
dose response curve ( A U G ) (the concentration X time) has been proposed in 
the calculation of threshold concentration used in experiment (Campling et al 
1991; Schroyens et al. 1990). However, this method is not clinically practical 
d u e to the limited cell n u m b e r ( Y a m a u e et al. 1992). Therefore, in s o m e 
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studies, two concentrations, C m a x X 1 and C m a x X 10 are used in the 
chemosensitivity testing system for gastric cancer ( Y a m a u e et al. 1992; Suto 
et al. 1989; Kimura et al. 1992; Maehara et al. 1987). C m a x is the peak 
plasma concentration found in patients. C m a x X 10 has been reported to 
have high predictable rate for drug sensitivity in gastric cancer patients (Fujita 
et al. 1998; Y a m a u e et al. 1992). In h u m a n solid carcinoma cell lines C m a x X 
10 induced a 5 0 % reduction in the dose-response curve. In fact, 
approximately C m a x X 10 is suitable for screening drug sensitivity in 
gastrointestinal cancer (Yamauchi et al. 1991). In addition, a positive 
correlation w a s obtained between the M T T assay and subrenal capsule assay 
( S R C ) assay at C m a x X 10 (Anai et al. 1987). In leukaemia chemosensitivity 
testing, drugs concentration at C m a x X 1 w a s considered to be the threshold 
value (Kaspers et al. 1991). However, in the ovarian cancer, drug 
concentration at C m a x X 2 w a s used (Konecny et al. 2000; Wilson et al. 1990) 
and in breast cancer, C m a x X 4 w a s used. Other types of the 
chemosensitivity test, for example, the clonogenic assay, approximately 
one-tenth of the C m a x is frequently used (Friedman et al. 1984; V o n Hoff et al. 
1983). However, C m a x are always varied depending on the method of 
measurement, dosage schedule, and individual patients (Bocci et al. 2000; 
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Tjuljandin et al. 1990; Twelves et al. 1991,). Therefore, the concentration 
selected for the tests is sometimes depended on the assay condition, assay 
system and individual preference. 
C o m p a r e d to other studies, the current study is more precise. T h e 
concentrations in this study covered C m a x X 1 and C m a x X 10 used in the 
previous study for gastric cancer. In addition, it covered the clinically 
achievable area under the curve (Park et al. 1987). T h e inhibition rates 
calculated from these six different concentrations give a relatively linear 
logarithm curve and twenty-four points were used to delineate the curve, so 
that the ICsocan determine more precisely. In contrast, if the single threshold 
concentration chosen is low, it m a y have overestimated the drug sensitivity, 
and if the threshold concentration chosen is high, it m a y have underestimated 
the drug sensitivity. 
Regarding the dose that inhibited the growth of 5 0 % of the cells (IC50), this 
cut-off value w a s selected based on the previous studies (Anai et al.1987; 
Carmichael 1987). However, other cut-off values have been chosen in other 
studies. For example, Weisenthal preferred ID30 as a cut-off point for drug 
sensitivity in hematological malignant (Weisenthal et al. 1986). Therefore, not 
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only the conditions in the assay vary, the criteria for evaluation also differ 
a m o n g studies. 
For the cell count and optical density，it w a s found that the O D reading is 
proportional to cell n u m b e r and accurately reflects the n u m b e r of living cells up 
to 100,000 cells/ well (Carmichael et al. 1987) and 300,000 cells/ well (Wilson 
et al. 1990). 
T o ensure the primary culture tumor cells are really tumor cells rather than 
fibroblasts or inflammatory cells, immunostaining for cytokeratin w a s 
performed. This step is a precaution against overgrowth of non-tumor cells. 
For the results to be useful clinically, the tests must be completed within a 
reasonable, expected period. This study has s h o w n that tumor samples can 
be cultured to produce sufficient n u m b e r of cells for drug tests in six weeks. 
This indicates that the assay can be applied to tumors obtained from patients 
for selection of post-operative chemotherapy. It is c o m m o n for adjuvant 
therapy to be given to patients approximately four to six w e e k s after surgical 
resection to allow for w o u n d healing and recovery after surgery. However, not 
all samples were able to generate enough cells for complete set of drug 
sensitivity tests within six weeks. This is sometimes due to the low n u m b e r of 
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cells initially obtained and s o m e tumor cells grew poorly and slowly. 
In fact, w h e n the tumor and its pseudo-biopsy are cultured simultaneously, 
their proliferation rates were similar. This indicates the proliferation rate of a 
tumor is related to the intrinsic property of that tumor. Inevitably, there will be 
s o m e tumors which will not grow with a sufficient yield for the full panel of 
chemosensitivity testing. 
5.3b T h e chemosensitivity results 
All the tumors in this study responded to the antitumor agents in a 
dose-dependent manner. T h e relative percentage of cell growth with respect 
to the controls decreases as the concentration increases suggesting fewer 
cells survive at high concentration than at low concentration. This illustrates 
the antitumor effectiveness is dependent on drug concentration. Cisplatin 
and all the anthracycline drugs are known to be dose dependent drugs. 
,*. 
T h e tumors responded to drugs differently and no two tumors s h o w e d the 
identical ICso. This indicates drug sensitivity is unique for each tumor. In 
addition, the distribution of the IC50 for all the cytotoxic drugs is wide with 
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differences in terms of m a n y thousand folds, indicating chemosensitivity of one 
tumor m a y be related to m a n y factors. This result is not unexpected because 
previous reports also s h o w e d similar p h e n o m e n o n in gastric tumor samples 
(Maehara et al. 1990; Suzuki et al. 2000) and in bladder cancer and renal cell 
cancer (Hirano et al. 1999). In fact, Boku et al. found that the IC50 differed 
widely for three gastric cancer cell lines tested (Boku et al. 2000). For 
example, in the case of adriamycin, the IC50 ranged from 0.0092 |ig/ml to 230 
|Lig/ml. T h e difference is over twenty hundreds folds in Boku's study. Thus, 
chemosensitivity of s o m e tumors cannot predict responses of other tumors. 
This broad distribution pattern again reinforces the need for drug sensitivity for 
individual tumor testing in vitro. 
T h e distribution patterns of chemosensitivity for the five drugs tested fall into 
normal or near normal (slightly skewed) curves. However, different patterns 
for 5-FU, adriamycin, and cisplatin are seen in study carried out by Suzuki et al. 
(Suzuki etal. 2000). 
. ‘ . 
F r o m the normal distribution，few patients are expected to be very sensitivity to 
the drugs and few are very resistant to the drugs with most patients expected 
to have partial response. D u e to the lack of clinical data，whether this 
104 
expectation held true is still undetermined. However, comparing the assay 
I C 5 0 of the four patients w h o by chance had received 5-FU as post-operative 
chemotherapy, the correlation between their clinical responses and the ICso is 
close to expectation. The patient with the highest ICso died with no evidence 
of response and the patient with very low I C 5 0 had disease free survival after 
16 months. Their I C 5 0 are located at the two ends of the normal curve. Thus, 
the assay s e e m s to have predictive values for these. T h e two remaining 
patients appeared to have partial response. This again suggests the 
chemosensitivity testing m a y be beneficial to patients. However, conclusion 
cannot be drawn without expanding the sample n u m b e r especially to include 
more cases within the partial response range. T h e cut-off values cannot be 
drawn until the criteria for defining the threshold of meaningful clinical 
response are available. 
For cisplatin and adriamycin which s h o w slightly skewed distribution, more 
tumors would expected to be "resistant" to the drugs. However, in the 
absence of clinical correlation, the interpretation is limited. 
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Moreover, this study s h o w e d that the stage and histological type of the tumors 
do not correlated with the I C 5 0 . Another study on chemosensitivity testing on 
gastric cancers also found no correlation between tumor sensitivity to drugs 
and clinical parameters including age, sex, stage, lymph node metastases 
(Fujita et al. 1998). T u m o r chemosensitivity cannot be predicted from the 
clinical parameters and this emphasizes the need for chemosensitivity testing 
in vitro. 
T h e chemosensitivity assay for the archival tumors and fresh tumors produced 
different I C 5 0 ranges for 5-FU. T h e archival tumors had been snapped frozen 
in liquid nitrogen for six to twelve months prior to the chemosensitivity 
experiments. T h e archival tumors，which might have contained multiple 
clones, were subjected to stressful conditions, such as the frozen temperature, 
s o m e clones less sensitive to the stress were selected and preferentially 
proliferated during culture for the chemosensitivity testing. A s a result, the 
survived cells were probably more resistant to stress conditions including 
antitumor agents. This hypothesis could account for the finding that the 
archive tumors were indeed significantly m o r e resistant to 5-FU than the fresh 
tumors. Thus, these samples probably did not represent the original tumors. 
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This finding illustrates the need for the immediate processing tumor samples 
for the chemosensitivity. This limitation is important because it m e a n s that a 
skilled technician must be available to handle the tumor samples soon after the 
gastrectomy. In addition, the tumors must be handled with care to ensure 
tumors are cultured free from contamination since the assay cannot be 
repeated using saved spare tissue. 
However, no significant difference in IC50 of the archival and fresh groups were 
found for adriamycin, cisplatin, daunorubicin, and epirubicin. Stress such as 
freezing appears to have different effects on tumor sensitivity to different 
drugs. 
S o m e drugs m a y have synergistic or antagonistic interaction. W h e n multiple 
drugs are administered simultaneously, the effects are more difficult to 
interpret. In fact, in almost all previous studies, only single agent w a s used. 
For tumors that s h o w n sensitivity to the drugs in vitro, the patients m a y not 
respond well to the treatment in vivo and vice versa. There are a n u m b e r of 
other factors that determines the final treatment outcome of the patients. 
These include host elements including patient age, nutritional status, drug 
intolerance due to drug toxicity to normal tissues and pharmcokinetics factors 
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such as drug absorption, distribution, drug metabolism and bioavailability. 
T h e chemosensitivity testing cannot entirely represent the host environment. 
For example, the three dimensional cell-cell interaction is lost in the in vitro test. 
Thus, the route of drug delivery to the cells is altered in the test. However, 
currently no other system can imitate the in vivo condition closer than the in 
vitro chemosensitivity testing. 
5.3c Chemosensitivity and MDR1 expression 
This study found no significant difference in terms of chemosensitivity between 
MDR1 positive and negative gastric cancers. This observation is shared by 
Lai et al. w h o reported no apparent correlation between cell line expression of 
M D R 1 and the sensitivity of the lines to five drugs, including adriamycin, 
etoposide, and cisplatin (Lai et al. 1989). Sensitivity to adriamycin treatment 
in fresh h u m a n gastric cancer cells did not correlate with the M D R 1 expression 
(Hotta et al. 1999). 
In contrast, there are very few published studies which reported correlation 
between chemosensitivity in vitro and MDR1 expression. O n e report found 
that gastric cancer cell lines, which have lower expression of MDR1 than the 
colorectal cancer cell lines, were relatively more sensitive to cisplatin, 
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adriamycin and mitomycin than the colorectal cancer cell lines (Park et al. 
1990). Park et al. utilized a relatively less sensitivity method, slot blot, to 
detect the presence of the MDR1 gene expression. In fact, they found the 
MDR1 expression in gastric cancer cell lines were rather low. Furukawa et al. 
have demonstrated that the expression of M D R 1 significantly correlated with 
the chemoresistance of the gastric cancer to adriamycin treatment (Furukawa 
et al 1998). 
MDR1 gene expression cannot entirely explain or predict the response of 
tumors to chemotherapy. At least a few other mechanisms have been 
suggested for multidrug resistance. O n e of them is the so called non-
P-glycoprotein mediated mechanism. T h e non-P-glycoproteins were first 
s h o w n to confer drug resistance in h u m a n lung cancer cell lines (Baas et al. 
1990). T h e proteins, including multidrug resistance associated protein ( M R P ) 
(Cole et al. 1992) and lung resistance protein (LRP) (Scheper et al. 1993) were 
later identified. M R P belongs to the A B C transporter family, having 1 5 % 
amino acid sequence homology with P-glycoprotein (Ramachandran and 
Melnick 1999) and L R P is a h u m a n vault protein (Scheffer et al. 1995). They 
are believed to reduce intracellular concentration of cytotoxic agents (Loe et al. 
1996). Other mechanisms include upregulation in drug detoxification system 
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by the glutathione-s-transferase-pi (GST-TI). It has been shown strongly 
associated with the resistant to cisplatin in gastric cancer cell lines is 
( O k u y a m a et al. 1994). Atypical M D R could also be due to an alteration in the 
level or sensitivity of topoisomerase II. 
5.3d Chemosensitivity and p53 immunohistochemical expression 
Except for cisplatin, there w a s no significant difference between the p53 
protein expression by immunostaining and the IC50 of the gastric tumors. 
However, p53 positive tumors have a higher ICso (more resistant to) for 
cisplatin. This implies that the p53 accumulation is only associated with the in 
vitro chemotherapeutic response of tumors to cisplatin and not a predictor of 
chemosensitivity at least in the other four drugs studied. 
This finding is in keeping with s o m e previous studies. T h e responses of 
gastric cancer patients to 5-fluorouracil based systemic chemotherapy were 
independent of the p53 expression (Yeh et al. 1999). T h e p53 expression did 
not correlate .with the clinical responses in breast cancer patients (Rozan 1998). 
In contrast, H a m a d a et al. have concluded that poor response of 
chemotherapy in patients with gastric and colorectal cancers is associated with 
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the p53 accumulation ( H a m a d a et al. 1996). C o m p a r e d with tumors showing 
no p53 protein expression, those with p53 accumulation are associated with 
shorter survival in pancreatic cancer patients treated with chemotherapy 
(Dergham et al. 1998). 
T h e relationship between p53 accumulation and in vitro chemosensitivity is still 
controversial. For instance, no relationship between p53 immunoreactivity in 
breast carcinoma and sensitivity for 5-FU, adriamycin and cisplatin in the in 
vitro assay w a s demonstrated (Yang et al. 2000). Similarly, Higashiyama et al. 
illustrate in vitro chemosensitvity to adriamycin and cisplatin for non-small cell 
lung carcinoma does not correlate with p53 expression (Higashiyama et al. 
1998). Nevertheless, they found the p53 accumulation does correlate with 
resistance to 5-FU (Higashiyama et al. 1998). In the case of gastric cancer, 
Nabeya et al. s h o w e d that the gastric cell lines expressing wild-type p53 
proteins is significantly more sensitive to 5-FU treatment but not to cisplatin 
treatment than cells expressing the mutant p53 (Nabeya et al. 1995). Hosaka 
et al. found correlation between the resistance to 5-FU and p53 expression but 
not for cisplatin and adriamycin (Hosaka et al. 2001). 
I l l 
Overall, the relationship between p53 expression and chemosensitivity or 
clinical response is still unclear. At present, p53 expression is most certainly 
not a reliable w a y to predict tumor response to antitumor drugs. 
5.3e Chemosensitivity and p53 mutations 
This study found no correlation between chemosensitivity and p53 mutations 
as detectable by S S C P and C S G E . 
Chemosensitivity response against different drugs m a y be associated with 
specific p53 mutation sites (Gangopadhyay et al. 2002). It has been shown 
cells bearing wild type p53 transfected with vector containing p53 with mutation 
at the codon 193 showed increased resistance to cisplatin, while the s a m e 
cells transfected with vector containing p53 with mutation at codon 143 
s h o w e d increased sensitivity to cisplatin (Gangoadhyay et al. 2002). In the 
s a m e study, cells transfected with vector containing mutation at codon 193 
were more sensitivity to UV-irradiation. This illustrates that mutation in 
V、 
different spots of gene could have diverged response (Pocard et al. 1996). 
Although, the mutations have not been confirmed by direct sequencing, the 
p53 mutations found in this study involved several exons. Hence, it is not too 
surprising if they have different effects on tumor chemosensitivity and not in a 
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single direction. 
In m y studies, the p53 mutation and p53 expression do not correlated to the 
sensitivity and resistant patterns. T h e only exception is the resistance to 
cisplatin, which correlated to the p53 protein accumulation. This implies other 
mechanisms are involved in the final determination of tumor sensitivity to most 
antineoplastic drugs, and most anticancer drugs affect different cellular 
pathways. Thus, the final sensitivity of a tumor in drug treatments is 
dependent on combination of these factors. 
In m y study, both the p53 dependent pathway and p53 independent pathway 
would have played a role in the determination of drug sensitivity. In fact, 
studies have suggested other cell cycle regulators besides p53 in the p53 
dependent pathway participate in the chemosensitivity, for instance, the cyclin 
dependent kinase inhibitor, p21. Increased resistance to cell 
cycle-dependent antineoplastic agents w a s found in the colon carcinoma cell 
lines w h e n the expression of p21 (Waf1) w a s induced (Schmidt et al. 2001). 
However, in another study, the opposite effect w a s found. Expression of 
p21in hepatoma cells enhanced chemosensitivity to cisplatin (Qin and N g 
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2001). This p h e n o m e n o n m a y be explained by the use of different cell types 
drugs, and methodologies in the induction of gene. Besides, the cells might 
have harbored other genetic alterations that were not known. Another cyclin 
dependent kinase inhibitor, p27, has also been suggested to be involved in the 
chemosensitivity. Tumors with high p27 expression were significantly more 
susceptible to anticancer drugs than those with low p27 expression (Yang et al. 
2000). 
Besides, components of the non-p53 pathway, have been s h o w n to effect 
chemosensensitivity. A n example is the PTEN, a tumor suppressor gene. 
T h e inactivation of this gene can constitutively activate P K B / A K T pathway. T h e 
loss of P T E N had been s h o w n to lead to up-regulation of the bcl-2 gene and 
contributed to chemoresistance (Huang et al. 2001). Ectopic expression of 
wild type P T E N in PTEN-mutant gliomas cells markedly sensitized them to 
irradiation (Wick et al. 1999). 
In addition, m e m b e r s in the Fas signaling pathway (CD95) correlated with the 
chemosensitivity. Fas receptor mediates apoptosis through the Fas ligand. 
Fas expression w a s s h o w n to directly correlate with drug-sensitivity (Lam et al. 
114 
2002). In addition, restoration of Fas protein activity in epigenetic silencing of 
Fas cells either by transfection of Fas or treatment with Trichostatin A (TSA), 
an inhibitor of histone deacetylase, restores chemosensitivity (Maecker et al. 
2002). Even the downstream proteins of the Fas signaling pathway, for 
examples, the caspase 3 and caspase 9 are involved in chemosensitivity 
(Debatin 1999). 
Although chemotherapeutic agents are known to induce D N A d a m a g e and 
cause the activation of p53 dependent pathway, the Akt pathway, the Fas 
signaling pathway m a y also be affected by anticancer drugs. It has been 
shown that an intact PI 3-K/Akt apoptotic pathway is required for the sensitivity 
to cisplatin (Asselin et al. 2001). In addition, activation of the Fas signaling 
pathway is involved in drug- and gamma-irradiation-induced apoptosis of 
medulloblastoma and glioblastoma cells (Fulda et al. 1998). 
5.3f Limitation of this study 
Although the chemosensitivity testing m a y aid the selection of the potentially 
effective drugs for the gastric cancer patients, there are s o m e limitations. 
First, the test cannot entirely mimic the clinical situation. T h e three-
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dimensional relationship of tumor cells might have been altered during the 
mechanical and enzymatic processes. Moreover, the extracellular matrix 
( E C M ) adhesion molecules on the epithelial gastric cells responsible for the 
cell adhesion and interaction might have been altered during processing. 
Besides, in the vivo system, the cells are surrounded by tumor stroma, in the 
present testing system, tumor cells were attached to the surface of culture 
plate in the culture m e d i u m without the surrounding cellular and extracellular 
components of the stroma. T h e tumor infiltrating leukocytes, fibroblasts and 
endothelial cells interact and influence tumor growth by production of cytokines 
and growth factors. These mediators could enhance or reduce the sensitivity 
of tumor in drug treatments. 
A s s h o w n by the comparison on the tumors and their pseudobiopies, the 
sensitivity of pseudobiopies in the drug tests did not correlate with the main 
bulk of tumor. This raises the question of representativeness of the 
chemosensitivity testing. It is known that the tumors are heterogeneous. 
T h e tumors collected m a y be different from the residual or recurrent tumor. 
T h e heterogeneity m a y result in variation in chemotherapeutic response and 
therefore, the predictive value of the testing m a y be less than anticipated. 
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In addition, the reliability of the chemosensitivity testing method is important. In 
m y study, not all collected tumors were able to grow in vitro. Only about 5 0 % 
of m y tumors were able to grow to sufficient cell n u m b e r for the drug tests 
although other studies have claimed a higher rate (Yamaue et al. 1992). 
Perhaps, this difference in proliferation rate m a y be due to the intrinsic 
properties of the tumors. In very occasional cases the failure w a s due to 
bacterial contamination. In fact, the chemosensitivity testing has been 
studied for three decades; the application of this test in clinical setting has so 
far been limited. 
Furthermore, as an oncologist, individual patient factors are the major concern 
in the selection of the appropriate drugs in treatment. However, these factors 
were not addressed in m y study. For example, drug absorption, metabolism, 
and excretion vary a m o n g patients. T h e drugs that were useful in vitro m a y 
not be suitable for the patients due to pharmacokinetic factors such as 
tolerance, idiosyncratic side-effects. Other physical conditions of patients 
require attention in the planning of chemotherapy. Since the kidney and liver 
are the two major sites for metabolism of most antineoplastic drugs, patients 
with reduced metabolic functions in these organs m a y be restricted in the 
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choices of drugs. The duration, frequency and the route of drug 
administration m a y influence the patients' acceptance of chemotherapy regime. 
Thus, patient factors have not been considered in the chemosensitivity testing. 
Lastly, the IC50 that w a s calculated in the drug tests has to be converted into 
clinical dose before the drug tests can apply in clinically doses. However, 
there is no defined, consensus on the formula for calculating the clinical dose 
using the in vitro concentration even though several formulae have been 
described. A current available formula allows the concentration used in vitro 
testing to convert into the clinical area under the curve (AUG). However, 
s o m e oncologists have challenged whether this formula is appropriate. O n e 
reason is that s o m e oncologists believe the A U G as compared to the peak 
plasma concentration (PPC), m a y not predict the antineoplastic drug toxicity. 
P P C is also imperfect because its value, using the s a m e administered route 
and dose, varies amongst individuals. 
5.3g Pseudobiopsies and large tumor samples 
T h e differences between the pseudobiopsies and their parent tumor were 
rather surprising considering that intra-assay replicates s h o w very similar 
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readings for both the pseudobiopsies and the big tumor tissue. There are 
several possible explanations. Firstly, in order to mimic usual endoscopic 
sampling procedures, the pseudobiopsies were sampled from the mucosal 
aspect at the edges of the ulcerative tumors. Sampling from ulcerated centre, 
though m a y give deeper tumor sample, clinically runs the risk of perforation. 
At the edge of the ulcerative tumor, it is more likely to be contaminated by 
benign epithelial cells. The main tumor specimen, on the other hand is most 
often taken from the central region of the tumor, less likely to be mixed with 
benign epithelium. Secondly, although this study had not shown significant 
correlation between chemosensitivity and tumors of different stages, it did not 
examine the homogeneity of the tumor cells in different part of the gastric wall. 
N o published study has examined this aspect so far. A s the method for 
analyzing MDR1 expression w a s by R T - P C R , the heterogeneity of the MDR1 
expression within these tumors w a s also unknown. It is possible that within a 
single tumor, the chemosensitivity varies from m u c o s a outwards. This would 
hardly be surprising, as tumor cells are known to acquire genetic changes as 
they m o v e from one tissue compartment to another. However, the implication 
is very important. T h e pseudobiopsies were studied with the aim of 
assessing the possibility of extending the chemosensitivity testing for 
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application in pre-operative chemotherapy. Based on this very small sample 
size, the results are not supportive of this application. Not only is there a 
need to study more cases, it is also important to try and perform separate 
assays on tumor cells from different layers of the gastric wall of each specimen. 
If the tumor cells from the mucosal aspect are indeed different from those on 
the serosal aspect, then the assay cannot be easily used in pre-operative 
chemosensitivity testing, or al least, serosal biopsies would have to be 
obtained. Experience from pre-operative chemotherapy tends to support this 
hypothesis, very frequently, tumor cells of the mucosal aspect were destroyed 
but those in the outer parts remain untouched. This p h e n o m e n o n had often 
been presumed to be related to different vascularity of the different layers of 
the gastric wall. 
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6 CONCLUSIONS 
This study has established an in vitro chemosensitivity testing assay for gastric 
cancer. T h e chemosensitivity testing can be completed in six weeks after 
gastrectomy, within a clinically acceptable period of time. This implies that 
this in vitro assay can have application in drug selection for post-operative 
adjuvant chemotherapy in the treatment of advanced gastric carcinoma. 
T h e chemosensitivity as represented by IC50 of each tumor is unique. T h e 
range of IC50 for each of the five drugs tested varies widely. There is no 
correlation between IC50 and any of the clinical parameters. 
p53 protein accumulation is found in 6 5 % of the tumors. T h e protein 
expression only correlates with the ICsofor cisplatin but not for the other four 
drugs. This suggests that p53 expression plays a role in chemosensitivity of 
s o m e drugs but not in most of the others, 
p53 gene mutation in exons 4-9 w a s demonstrated in 5 2 % of tumor samples 
by S S C P / C S G E . A total of 18 band shifts were found in 15 samples. 
Mutation in exon 4 w a s the most frequent and no mutation w a s found in exon 7. 
N o correlation between p53 mutation and I C 5 0 w a s found. 
MDR1 overexpression w a s demonstrated in 14 (56%) of the tumor samples. 
There were six cases in which the MDR1 expression w a s detected in the 
normal tissue. Five of them had MDR1 overexpression in the tumors and one 
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had down-regulation of MDR1 expression in the tumor. This suggests that 
MDR1 gene expression is either absent or down-regulated in the normal tissue 
and up-regulated in the tumors. The MDR1 gene expression did not correlate 
with the IC50. 
Molecular markers, p53 and MDR1, and clinical parameters are poor 
predictors of chemosensitivity. These observations suggest that 
chemosensitivity is an intrinsic characteristic of the tumor. Standardized in 
vitro chemosensitivity assay is feasible and useful in providing information, 
which cannot be obtained by the molecular methods or clinical data, for drug 
selection in adjuvant chemotherapy. 
Future studies should focus on the correlation of IC50 with clinical response. 
This will determine the cut-off values of IC50 for chemosensitive or resistant 
categories. T h e p53 mutations should also be confirmed by direct 
sequencing for a more accurate correlation. 
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APPENDIX 1 TNM Classification of Gastric Adenocarcinoma 
T- Primary Tumor 
T x Primary tumor cannot be assessed 
T O N o evidence of primary tumor 
丁is Carcinoma in situ: intraepithelial tumor without invasion of the 
lamina propria 
T 1 T u m o r invades lamina propria or submucosa 
T 2 T u m o r invades muscularis propria or subserosa 
T 3 T u m o r penetrates serosa (visceral peritoneum) 
without invasion of adjacent structures 
T 4 T u m o r invades adjacent structures 
N- Regional Lymph Nodes 
N X Regional lymph nodes cannot be assessed 
N O N o regional lymph node metastasis 
N 1 Metastasis in 1 to 6 regional lymph nodes 
N 2 Metastasis in 7 to 15 regional lymph nodes 
N 3 Metastasis in more than 15 regional lymph nodes 
M- Distant Metastasis 
M X Distant metastasis cannot be assessed 
M O N o distant metastasis 
M 1 Distant metastasis 
APPENDIX 2 Stage Grouping for Gastric Adenocarcinoma 
Stage T u m o r Size N o d e Status Distant Metastases 
0 Tis r ^  
1A ^ N O 一 M O 
1B m M O 
T2 M O 
II T1 N 2 — M O 一 
T2 N 1 — M O — 
M O 
IHA T2 N 2 — M O 一 
T ^ m M O 
T4 m M O 
HIB T 3 N 2 m 
T4 m M O 
IV T4 N 2 — M O — 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































APPENDIX 4 List of Drug Tests Performed on Tumors 
Drugs  
case 5 fluorouracil Adriamycin Cisplatin Daunorubicin Epirubicin 
_ J _ X 一 X X 一 X X 
2 X X N.D. “ X N.D. 
3 N.D. — X — X — X N . D . — 
4 X X ~~~N.D. N.D. X 
5 X X X N.D. i m 
6 r m X ~ ~ N . D . X N.D. 
7 N.D. ~ X " X X X 
8 X — X 一 X X X 
9 X — X — N.D. — X N.D. 一 
10 X — X 一 X — X X 
11 X X 一 X — X X 
12 X X 一 X X X 
13 X X 一 X — X X 
1 4 X 一 X — X 一 X X 
15 ~ X X ~ X X X — 
16 X N.D. — X N.D. X — 
1 7 — X — X — X X X 一 
18 ~ X X ~ X X X — 
19 ~ X X ~ X X X 一 
20 X — X 一 X — X X 
2 1 — X — X — X X X 一 
22 X 一 X 一 X X — X 
23 ~ X ~ X ~ X X X 一 
2 4 i m N.D. 一 X N.D. “ X 
25 X — X 一 X — X X 
2 6 X 一 X ~ X X X 
2 7 — X — X — X X X — 
28 X — X 一 N.D. X X 
2 9 — X — X — X X X 一 
3 0 — X X ~ X ~ X X 
31 I X I X I X I X N.D. 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































APPENDIX 9 Clinicopathological Parameters and p53 Protein Expression 
p53 positive P53 jotal  
negative 
+(<1/3) I++(1/3 to 2/3)1 +++(>2/3) -
S^ “ 
M ^ 4 2 — 6 6 ^ 
Female 2 2 4 5 13 
total 6 4 10 11 
^ + I ++ I ； n ~ 
<59 years 4 3 4 5 ^ 
>59 years 2 1 6 6 
total 6 4 10 — 1 1 — 3 1 
Stage + ++ +++ I ^ ~ 
I 一 1 1 3 2 二 ^ ^ 
[J 3 1 0 2 
“‘ 一 2 2 5 T ^ J l I 
0 0 2 0 ‘~2~ 
total 6 4 10 U 
Type + ++ +++ I n ~ 
Intssti 门 5 0 7 7 ig 
Diffuse 0 4 3 2 9 ~ 
Mixed 1 0 0 2 ^ 
Total 6 4 10 U 3?~~ 
L y m p h node metastasis + ++ ； “ ~ 
Absent 4 2 4 3 ^ ^ 
Present 2 2 6 8 
6 I 4 丨 10 11 31 
APPENDIX 10 Clinicopathological Parameters and p53 Genetic Mutations 




Male 11 7 18 
Female 4 6 11 
t o ^ 15 — 14 ^ 2 9 
^ — 
Less than 59 8 7 15 
Greater than 59 7 7 14 
t ^ ^5 14 ^ ^ ~ 
Stage 
1 5 2 7 ~ ~ 
2 2 一 4 6 
3 6 8 
4 2 一 0 2 
t ^ ^5 14 ^ 
Type m i i i i i z i ^ z z i z z i i i i z i i z i i z i z i 
Intestinal 10 8 18 
Diffuse 5 4 9 
Mixed 0 2 2 
Total ^ 13 ^ 
L y m p h node metastasis 
Absent 7 6 13 
Present 8 8 16 
— I 15 14 29 
APPENDIX 11 Distribution of p53 mutations Detected by SSCP/CSGE 
















APPENDIX 12 Clinical Parameter and MDR1 Overexpression 
MDR1 positive MDR1 negative Total 
Sex 
Male 8 7 15 
Female 6 4 10 
T ^ 14 11 ^ 
^ Z Z ^ Z Z Z Z Z I I L Z Z I Z Z Z Z Z n ^ ^ Z ^ Z ^ ! ! ! ^ ^ ~ 
Less than 59 8 5 13 
Greater than 59 6 6 12 
T ^ U 11 ^ 
Stage 
1 2 2 4 
2 4 2 6 
3 7 6 13 
4 1 1 2 
T ^ 14 11 ^ 
T ^  
Intestinal 11 4 15 
Diffuse 1 7 8 
Mixed 2 0 2 
Total 14 11 25 
L y m p h node metastasis 
Absent 6 5 11 
Present 8 6 14 
Total 14 11 25 
APPENDIX 13 Details of p53 and MDR1 Results 
~ “ IHC of S S C P / C S G E Normal MDR1 Tumors MDR1 MDR1 
C a s e 
^ of p53 expression expression expression 
1 + mutation N.D. N.D. N.D. 
2 - mutation - - -
3 ++ mutation - - . 
4 - mutation N.D. N.D. N.D. 
5 - 门 0 门 6 - + + 
6 - mutation - - -
7 ++ mutation - - -
8 +++ mutation - - -
9 + none + ++ + 
1 0 - mutation - + + 
11 +++ 门o 门 6 - + + 
12 +++ no 门 6 - + + 
13 +++ mutation - - -
1 4 一 门 0门 6 + - -
1 5 + 门 0 门 6 + + + + 
16 + none + ++ + 
17 +++ mutation - - _ 
18 - none - ++ + 
19 - none + ++ + 
2 0 none - - I 
2 1 + none - + + 
2 2 +++ mutation + ++ + 
23 +++ mutation - + + 
2 4 ++ mutation - _ I 
25 + mutation - + + 
26 ++ none - - _ 
2 7 - no门6 - + + 
28 +++ mutation N.D. f m r m 
29 +++ none N.D. 一 N.D. i m 
3 0 ： N.D. 一 N.D. _ N.D. N.D. 
~ 3 1 - N.D. N.D. N.D. N.D.   
none=no mutation, N.D. = not determined 
FIGURE 1 Graphs showing examples of dose dependent tumor growth 
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FIGURE 2 Distribution of log I C 5 0 for All Five Drugs Tested 
2a. Distribution of log ICso of the fresh samples 
in 5-FU treatment 
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2b. Distribution of log ICSO of the archive samples 
in 5-FU treatment 
5 
$ 4 • 
-
" t t t t ^ d 
<5.000 5.00-5.19 6.20-5.39 5.40-5.60 >5.6 
l o g I C 5 0 
2c. Distribution of log IC50 in adriamycin treatment 
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2f. Distribution of the log IC50 in epirubicin treatment 
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FIGURE 3 Distribution of log IC50 and Tumor Stage 
in All Five Drugs Tests 
3a. Distribution of log ICso of the archive samples 
and tumor stage in 5-FU treatment 
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3d. Distribution of log ICSO and tumor stages 
in cisplatin treatment 
4.50 
4.00 ——^  
A 
3.50 - X — — i i  
T A • 
3.00 • • ’ • X  
I 2.50 參 ^ — — ^ 网 
g> 2.00 ~ ~ m A ~ ^ • 丁2 
A • 丁 3 
1 P.0  
1.5。 • • . • • • 丛 
1.00 — 
0.50 • 
0.00 ‘ ‘ 
3e. Distribution of log IC50 and tumor stage 






S • • • • • 丁 2 
^ 3 . 0 0 秦 乂 画 灰 、 ~ ^ ^ ^ • 丁 3 
o X • • x T 4 
2.00 ——S"^ ^ ~ ~ i  
1.00 ^  
• 
0.00 ‘ ‘ ‘ 
3f. Distribution of log IC50 and tumor stage 
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FIGURE 4 Immunohistochemistry for p53 protein expression 
4a. p53- tumor (XI0 objective) 4b. p53 + tumor (XI0 objective) 
4c. p53 ++ tumor (X20 objective) 4d. p53 +++ tumor (X20 objective) 
FIGURE 5 Detection of p53 mutation by CSGE 
5a Detection of p53 mutation in exon 4 by CSGE 
I i 
^ ~ ~ Mutated 
^ ~ Normal 
Eight samples were screened for mutation by C S G E . 
Sample 17 and 28 showed band shift (indicated by the red arrows). 
FIGURE 5b Detection of p53 mutation in exon 8/9 by CSGE 
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H H ^ ~ ~ Mutated conformation 
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Eleven samples were screened for mutation in exon 8/9 by C S G E . 
Sample 8 and 22 showed band shift (indicated by the red arrows). 
FIGURE 6 Detection of mutation in p53 exon 6 by SSCP 
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Cases 25 and 4 normal and tumor samples were 
screened for mutation in exon 6 by SSCP. Case 25 
showed a band shift (indicated by the arrow). 
FIGURE 7 Representative results of MDR1 overexpression 
7a. RT-PCR of MDR1 gene 
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